<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">70885</article-id><article-id pub-id-type="doi">10.7554/eLife.70885</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>A MET-PTPRK kinase-phosphatase rheostat controls ZNRF3 and Wnt signaling</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-155383"><name><surname>Kim</surname><given-names>Minseong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3927-4899</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-155385"><name><surname>Reinhard</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-211467"><name><surname>Niehrs</surname><given-names>Christof</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9561-9302</contrib-id><email>niehrs@dkfz.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Division of Molecular Embryology, DKFZ-ZMBH Alliance, Deutsches Krebsforschungszentrum (DKFZ)</institution><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution>Institute of Molecular Biology (IMB)</institution><addr-line><named-content content-type="city">Mainz</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nusse</surname><given-names>Roel</given-names></name><role>Reviewing Editor</role><aff><institution>Stanford University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Eisen</surname><given-names>Michael B</given-names></name><role>Senior Editor</role><aff><institution>University of California, Berkeley</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>30</day><month>09</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e70885</elocation-id><history><date date-type="received" iso-8601-date="2021-06-09"><day>09</day><month>06</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-09-29"><day>29</day><month>09</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Kim et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Kim et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-70885-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-70885-figures-v2.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="article-reference" xlink:href="10.7554/eLife.51248"/><abstract><p>Zinc and ring finger 3 (ZNRF3) is a transmembrane E3 ubiquitin ligase that targets Wnt receptors for ubiquitination and lysosomal degradation. Previously, we showed that dephosphorylation of an endocytic tyrosine motif (4Y motif) in ZNRF3 by protein tyrosine phosphatase receptor-type kappa (PTPRK) promotes ZNRF3 internalization and Wnt receptor degradation (Chang et al 2020). However, a responsible protein tyrosine kinase(s) (PTK) phosphorylating the 4Y motif remained elusive. Here we identify the proto-oncogene MET (mesenchymal-epithelial transition factor) as a 4Y kinase. MET binds to ZNRF3 and induces 4Y phosphorylation, stimulated by the MET ligand HGF (hepatocyte growth factor, scatter factor). HGF-MET signaling reduces ZNRF3-dependent Wnt receptor degradation thereby enhancing Wnt/β-catenin signaling. Conversely, depletion or pharmacological inhibition of MET promotes the internalization of ZNRF3 and Wnt receptor degradation. We conclude that HGF-MET signaling phosphorylates- and PTPRK dephosphorylates ZNRF3 to regulate ZNRF3 internalization, functioning as a rheostat for Wnt signaling that may offer novel opportunities for therapeutic intervention.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>endocytosis</kwd><kwd>HGF-MET</kwd><kwd>PTPRK</kwd><kwd>tyrosine kinases</kwd><kwd>Wnt signaling</kwd><kwd>ZNRF3</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB 1324/2, B01</award-id><principal-award-recipient><name><surname>Kim</surname><given-names>Minseong</given-names></name><name><surname>Reinhard</surname><given-names>Carmen</given-names></name><name><surname>Niehrs</surname><given-names>Christof</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>HGF-MET signaling phosphorylates- and PTPRK dephosphorylates ZNRF3 to regulate ZNRF3 internalization, functioning as a rheostat for Wnt signaling.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Wnt signaling plays a pivotal role in embryonic development and in maintaining organ homeostasis (<xref ref-type="bibr" rid="bib44">MacDonald et al., 2009</xref>; <xref ref-type="bibr" rid="bib16">Clevers and Nusse, 2012</xref>; <xref ref-type="bibr" rid="bib37">Kim et al., 2013</xref>). Wnt signaling is tightly regulated at numerous levels of the pathway (<xref ref-type="bibr" rid="bib50">Niehrs, 2012</xref>; <xref ref-type="bibr" rid="bib51">Nusse and Clevers, 2017</xref>; <xref ref-type="bibr" rid="bib3">Anthony et al., 2020</xref>). One prominent mode of regulation occurs at the level of the Wnt receptors LRP6 (low-density lipoprotein receptor-related protein 6) and FZD (Frizzled class receptors), which are antagonized by various secreted factors and activity-modulated by phosphorylation of their cytoplasmic tail (<xref ref-type="bibr" rid="bib49">Niehrs and Shen, 2010</xref>; <xref ref-type="bibr" rid="bib18">Cruciat and Niehrs, 2013</xref>). In addition, Wnt receptor availability at the plasma membrane is controlled by ER chaperones (<xref ref-type="bibr" rid="bib31">Hsieh et al., 2003</xref>; <xref ref-type="bibr" rid="bib68">Weekes et al., 2012</xref>; <xref ref-type="bibr" rid="bib6">Berger et al., 2017</xref>) as well as by the E3 ubiquitin ligase ZNRF3 and its functional homolog RNF43. These transmembrane proteins act as negative feedback regulators of Wnt signaling that promote receptor degradation by ubiquitylating and internalizing cell surface LRP6 and FZD (<xref ref-type="bibr" rid="bib28">Hao et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Koo et al., 2012</xref>). More recently, ZNRF3 was shown to also internalize and degrade the BMP receptor type 1A and thereby antagonize BMP signaling (<xref ref-type="bibr" rid="bib43">Lee et al., 2020</xref>). ZNRF3/RNF43 are counteracted by secreted proteins of the R-spondin family, which sequester ZNRF3/RNF43 in conjunction with LGR4/5/6, thereby leading to the membrane clearance of ZNRF3/RNF43 (<xref ref-type="bibr" rid="bib11">Carmon et al., 2011</xref>; <xref ref-type="bibr" rid="bib19">de Lau et al., 2011</xref>; <xref ref-type="bibr" rid="bib25">Glinka et al., 2011</xref>; <xref ref-type="bibr" rid="bib28">Hao et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Koo et al., 2012</xref>).</p><p>ZNRF3 and RNF43 play important roles in adult stem cells and in tumorigenesis (<xref ref-type="bibr" rid="bib20">de Lau et al., 2014</xref>; <xref ref-type="bibr" rid="bib29">Hao et al., 2016</xref>). Yet, little is known about how ZNRF3 and RNF43 are regulated intracellularly (<xref ref-type="bibr" rid="bib35">Jiang et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Ci et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Giebel et al., 2021</xref>). We recently discovered an endocytic signal in the cytoplasmic domain of ZNRF3 consisting of four consecutive tyrosine residues (4Y motif: <bold>Y</bold>ETM<bold>Y</bold>QH<bold>YY</bold>) that regulates ZNRF3- and in turn Wnt receptor internalization (<xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref>). Tyrosine motifs play a critical role in regulating endocytosis of transmembrane proteins and unphosphorylated YXXXφ and φXXY sites as well as YXXφ (<italic>φ</italic> = bulky hydrophobic amino acid) serve as internalization motifs (<xref ref-type="bibr" rid="bib71">Zhang and Allison, 1997</xref>; <xref ref-type="bibr" rid="bib55">Roush et al., 1998</xref>; <xref ref-type="bibr" rid="bib8">Bonifacino and Traub, 2003</xref>; <xref ref-type="bibr" rid="bib56">Royle et al., 2005</xref>). Phosphorylation of the 4Y motif prevents ZNRF3 internalization and stabilizes Wnt receptors at the cell surface. Conversely, dephosphorylation of the 4Y motif by PTPRK (protein tyrosine phosphatase receptor-type kappa) promotes ZNRF3 internalization and Wnt receptor clearance from the cell surface, thereby inhibiting Wnt signaling (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). While our report showed that 4Y phosphorylation regulates ZNRF3 trafficking, it left unanswered the crucial question of what is the protein tyrosine kinase(s) (PTK) responsible for 4Y phosphorylation.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Identification of SRC and MET as ZNRF3 kinases.</title><p>(<bold>A</bold>) Model for tyrosine phosphorylation regulating ZNRF3 and Wnt signaling (<xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref>). ZNRF3 E3 ubiquitin ligase reaching the plasma membrane is co-internalized with Wnt receptors and targets them for lysosomal degradation to reduce Wnt signaling. An unphosphorylated 4-tyrosine (4Y) motif serves as ZNRF3 internalization signal. The phosphatase PTPRK dephosphorylates and unmasks the 4Y motif, promoting internalization and lysosomal targeting of ZNRF3 and Wnt receptors, and reducing Wnt signaling. PTPRK is counteracted by an unknown tyrosine kinase(s) that phosphorylates the 4Y motif, impairs ZNRF3/Wnt receptor internalization, and increases Wnt signaling. Created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">Biorender.com</ext-link>. (<bold>B</bold>) Scheme of 4Y PTK candidate selection. Eighteen tyrosine kinases were selected by combined in silico prediction and reported cellular localization. Kinase inhibitor screening (<bold>C</bold>) was then conducted for validation. (<bold>C</bold>) Inhibitor screen for ZNRF3 4Y kinases. TetOn ZNRF3-HA H1703 cells were treated with 40 inhibitors targeting 18 PTKs selected as shown in (<bold>B</bold>). pTyr-ZNRF3 was analyzed by immunoblot for pan-phosphotyrosine and normalized to total ZNRF3. Results from two independent screens were pooled to generate the dot graph. X-axis indicates the relative tyrosine phosphorylation of ZNRF3 upon inhibitor (Tki) treatment relative to DMSO control, y-axis indicates p-value. Three kinases (SFK, MET, FAK) with phosphorylation inhibition ≥80% and p-value ≤ 0.05 were selected for downstream analysis and are highlighted. (<bold>D</bold>) Analysis of pTyr-ZNRF3 in HEK293T cells co-transfected with ZNRF3-HA and MET-myc, myc-FAK or SRC. Cell lysates were pulled down with anti-HA antibody and subjected to immunoblot analysis using the indicated antibodies. Data show a representative result from three independent experiments with similar outcome. Black arrowhead: Immature MET precursor. White arrowhead: Mature, processed MET (β-chain). Source files of all blots used in this figure are available in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Uncropped immunoblot images for <xref ref-type="fig" rid="fig1">Figure 1D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-70885-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70885-fig1-v2.tif"/></fig><p>Here we identify the proto-oncogene MET (mesenchymal-epithelial transition factor/hepatocyte growth factor receptor) as a 4Y kinase. MET is a single transmembrane receptor PTK with important roles in promoting cell growth and differentiation during embryonic development, organogenesis, and cancer progression (<xref ref-type="bibr" rid="bib66">Trusolino et al., 2010</xref>; <xref ref-type="bibr" rid="bib22">Gherardi et al., 2012</xref>; <xref ref-type="bibr" rid="bib9">Bradley et al., 2017</xref>). The only known ligand of MET is hepatocyte growth factor/scatter factor (HGF/SF). HGF binding to MET mediates dimerization and enzymatic activation of MET to engage multiple downstream effectors such as AKT, MAPK, STAT, and SRC (<xref ref-type="bibr" rid="bib66">Trusolino et al., 2010</xref>; <xref ref-type="bibr" rid="bib45">Malik et al., 2020</xref>). HGF-MET signaling also cross-talks with Wnt signaling pathway at various levels (<xref ref-type="bibr" rid="bib54">Papkoff and Aikawa, 1998</xref>; <xref ref-type="bibr" rid="bib48">Monga et al., 2002</xref>; <xref ref-type="bibr" rid="bib4">Apte et al., 2006</xref>; <xref ref-type="bibr" rid="bib32">Huang et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">Koraishy et al., 2014</xref>; <xref ref-type="bibr" rid="bib13">Chaudhary et al., 2019</xref>). Here we show that HGF stabilizes binding of MET to ZNRF3 and induces tyrosine phosphorylation of the 4Y motif. HGF-MET signaling attenuates endocytosis of ZNRF3 and thereby stabilizes Wnt receptors at the cell surface, leading to β-catenin activation. Our results establish an HGF-gated rheostat whereby phosphorylation/dephosphorylation by MET and PTPRK tunes ZNRF3 endocytic trafficking and Wnt receptor availability.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>MET is a ZNRF3 4Y kinase</title><p>To identify PTKs responsible for phosphorylating the 4Y motif of ZNRF3, we consulted the kinome database GPS 3.0 (<xref ref-type="bibr" rid="bib69">Xue et al., 2011</xref>) for computational prediction of phosphorylation sites with their cognate protein kinases, which revealed a number of putative 4Y tyrosine kinases (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). To this list, we added some additional PTKs that either display transmembrane (RTKs) or cortical localization. To screen these 18 PTKs, we utilized H1703 human lung adenocarcinoma cells harboring doxycycline (Dox)-inducible ZNRF3-HA (TetOn ZNRF3-HA) to overcome poor transfection efficiency of this cell line as well as the general lack of antibodies against endogenous ZNRF3 (<xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref>). We monitored tyrosine phosphorylation of ZNRF3 by immunoblot using a pan phospho-Tyr (pTyr) antibody upon treatment with a selected library of 40 chemical inhibitors targeting the 18 PTKs. To increase sensitivity of pTyr-ZNRF3 detection, here and in other experiments monitoring specifically pTyr-ZNRF3, we employed bafilomycin to prevent lysosomal degradation and stabilize the protein (<xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref>). Among 18 selected candidate kinases, inhibition of SRC family kinases (SFKs), focal adhesion kinase (FAK; encoded by PTK2), and MET showed significant reduction on pTyr-ZNRF3 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). To validate this finding, we monitored pTyr-ZNRF3 upon overexpression of SRC, FAK, and MET in HEK293T cells (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Overexpression of MET strongly- and SRC weakly phosphorylated ZNRF3 (lanes 5–6), while FAK (lane 7) had no effect. SRC, YES, and FYN are widely expressed SFKs with overlapping functions (<xref ref-type="bibr" rid="bib60">Stein et al., 1994</xref>; <xref ref-type="bibr" rid="bib64">Thomas et al., 1995</xref>), but we counted-out YES as candidate since a YES-specific inhibitor had no effect in the initial screen. We therefore continued with individual or combined knockdown of SRC, FYN, and MET by siRNAs and found that depletion of all three kinases, most prominently of MET, reduced ZNRF3 phosphorylation (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; compare lane 2 to lanes 3, 4, or 6). Triple knockdown of SRC, FYN, and MET nearly eliminated the pTyr signal to background (lanes 7 vs. 1). Of note, while MET is often amplified in cancer cells, H1703 cells harbor normal MET copy number (<xref ref-type="bibr" rid="bib42">Kubo et al., 2009</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>MET is a ZNRF3 4Y kinase.</title><p>(<bold>A</bold>) Tyrosine phosphorylation of ZNRF3 requires endogenous MET and SRC. pTyr-ZNRF3 was monitored in TetOn ZNRF3-HA H1703 cells upon siRNA knockdown of <italic>SRC</italic>, <italic>FYN</italic>, <italic>MET</italic> or combinations as indicated. Cells were induced with Dox for 48 hr before harvest. Cells without Dox treatment were used as control for background pTyr signal. Data show a representative result from two independent experiments with similar outcome. (<bold>B</bold>) Analysis of pTyr-ZNRF3 in TetOn ZNRF3-HA H1703 cells upon siRNA knockdown of <italic>SRC, FYN, MET</italic> or combination as indicated. Lysates were pulled down with anti-HA antibody or control IgG and subjected to immunoblot analysis with the indicated antibodies. (<bold>C</bold>) Visualization of normalized pTyr-ZNRF3 from immunoblots (<bold>A</bold>) and ZNRF3 pulldown (<bold>B</bold>) as a heat map. Background signal (lane 1 from (<bold>A, B</bold>)) was subtracted from pTyr-ZNRF3 before normalization to total ZNRF3. Color code is represented on the right. (<bold>D</bold>) ZNRF3 binds endogenous MET but not SRC. Co-immunoprecipitation (Co-IP) analysis in TetOn ZNRF3-HA H1703 cells upon siRNA knockdown of <italic>MET</italic> or <italic>SRC</italic>. Data show a representative result from three independent experiments with similar outcome. Black arrow: IgG heavy chain. Black arrowhead: MET. White arrowhead: expected position of SRC. (<bold>E</bold>) MET but not SRC is a 4Y-specific kinase. Tyrosine phosphorylation of ZNRF3-HA or ZNRF3(Δ4Y)-HA in HEK293T cells co-transfected with the indicated kinases. Lysates were pulled down with anti-HA antibody and subjected to immunoblot analysis using the indicated antibodies. Data show a representative result from three independent experiments with similar outcome. (<bold>F</bold>) MET and PTPRK oppose each other on 4Y phosphorylation. Analysis of pTyr-ZNRF3 in TetOn ZNRF3-HA H1703 cells upon siRNA knockdown of <italic>PTPRK</italic> and/or overnight crizotinib treatment as indicated. Lysates were pulled down with anti-HA antibody or control IgG and subjected to immunoblot analysis with the indicated antibodies. Ratio, relative pTyr-ZNRF3 normalized to total ZNRF3. Data show a representative result from two independent experiments with similar outcome. (<bold>G</bold>) Model: MET and PTPRK phosphorylate and dephosphorylate the 4Y motif on ZNRF3, respectively. Created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">Biorender.com</ext-link>. Source files of all blots used in this figure are available in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. Source files of densitometric analysis for heat map in (<bold>C</bold>) are available in <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>. A source file of densitometric analysis for (<bold>F</bold>) is available in <xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Uncropped immunoblot images for <xref ref-type="fig" rid="fig2">Figure 2A–B, D–F</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-70885-fig2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Densitometric analysis of immunoblots for <xref ref-type="fig" rid="fig2">Figure 2A–B</xref> to generate heap map for <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-70885-fig2-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Densitometric analysis of immunoblots for <xref ref-type="fig" rid="fig2">Figure 2F</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70885-fig2-data3-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70885-fig2-v2.tif"/></fig><p>Since SFKs are downstream effectors of MET (<xref ref-type="bibr" rid="bib30">Herynk et al., 2007</xref>; <xref ref-type="bibr" rid="bib7">Bertotti et al., 2010</xref>), we wondered whether the effect of MET knockdown on pTyr-ZNRF3 was indirectly caused by reduced SFK activity. However, the activity of SFKs as monitored by pY416 autophosphorylation was unchanged upon knockdown of MET (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), suggesting that MET directly regulates pTyr-ZNRF3 independently of SFKs.</p><p>Reduced pTyr-ZNRF3 caused by MET depletion was confirmed by pulldown of ZNRF3 (<xref ref-type="fig" rid="fig2">Figure 2B–C</xref>). Moreover, ZNRF3 robustly bound to endogenous MET, whereas no binding to SRC was detected (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). To test whether SRC or MET indeed mediates tyrosine phosphorylation of the 4Y motif, we transfected them along with the wild-type (Wt) ZNRF3 or mutant ZNRF3(∆4Y) lacking the 4Y motif and monitored pTyr-ZNRF3 levels (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). ZNRF3 phosphorylation by MET was dramatically reduced with ZNRF3(∆4Y), although not completely abolished, suggesting some 4Y-independent phosphorylation by MET. In contrast, no reduction but a strong increase was observed for SRC-mediated ZNRF3 phosphorylation (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). This unexpected increase may be explained by our previous observation that ZNRF3(∆4Y) preferentially localizes at the cell surface (<xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref>) where activated SRC also resides.</p><p>We previously showed that depletion of PTPRK induces 4Y phosphorylation of ZNRF3 by opposing the action of an unknown tyrosine kinase (<xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref>). To address whether PTPRK opposes MET in this context, we carried out ‘rescue’ experiments with the competitive MET kinase inhibitor Crizotinib. Indeed, enhanced pTyr-ZNRF3 induced by PTPRK siRNA depletion was rescued by Crizotinib (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). This PTPRK-MET double-inhibition experiment supports that MET and PTPRK oppose each other in ZNRF3 4Y phosphorylation (<xref ref-type="fig" rid="fig2">Figure 2G</xref>).</p><p>Taken together, our results show that MET binds ZNRF3 and is both necessary and sufficient for 4Y phosphorylation, supporting the notion that MET is indeed a 4Y kinase that opposes PTPRK. Of note, MET is likely not the only 4Y kinase since in early <italic>Xenopus</italic> embryos, ZNRF3 dephosphorylation by PTPRK plays a role during Spemann organizer patterning (<xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref>) before the onset of significant Met expression (<xref ref-type="bibr" rid="bib39">Koibuchi et al., 2004</xref>) and hence we did not analyze Met in <italic>Xenopus</italic>. SRC on the other hand promotes ZNRF3 phosphorylation likely at a site different from the 4Y motif and was not further analyzed. In the following analysis, we therefore focused on the MET-ZNRF3 interaction.</p></sec><sec id="s2-2"><title>HGF-MET signaling triggers 4Y phosphorylation of ZNRF3</title><p>Given that HGF ligand binding to MET initiates its kinase activity, we tested if HGF-MET signaling stimulates ZNRF3 phosphorylation. We treated TetOn ZNRF3-HA H1703 cells with human HGF and analyzed pTyr-ZNRF3 after pulldown. Indeed, HGF strongly induced pTyr-ZNRF3, and this induction was reduced by the MET inhibitor Crizotinib (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), as well as by siRNA-mediated knockdown of MET (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Moreover, Co-IP analysis showed that HGF treatment increased the binding of ZNRF3 to endogenous MET in a time-dependent fashion, peaking at 30 min of HGF treatment (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Increased binding of ZNRF3 to MET occurred despite total MET levels slightly decreasing after 15 min HGF treatment, the latter likely reflecting ligand-induced MET internalization and degradation (<xref ref-type="bibr" rid="bib62">Taher et al., 2002</xref>). Furthermore, while HGF strongly induced phosphorylation of Wt ZNRF3, phosphorylation of ZNRF3(∆4Y) was barely affected (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), corroborating that HGF-MET signaling mainly targets the 4Y motif. We conclude that HGF-MET signaling induces 4Y phosphorylation of ZNRF3 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>HGF-MET signaling triggers 4Y phosphorylation of ZNRF3.</title><p>(<bold>A</bold>) HGF induces tyrosine phosphorylation of ZNRF3 and requires MET kinase activity. Analysis of pTyr-ZNRF3 in TetOn ZNRF3-HA H1703 cells upon overnight Crizotinib treatment. HGF was added for 2 hr before harvest. Lysates were pulled down with anti-HA antibody or control IgG and subjected to immunoblot analysis. Data show a representative result from two independent experiments with similar outcome. (<bold>B</bold>) HGF-induced tyrosine phosphorylation of ZNRF3 requires MET. pTyr-ZNRF3 in TetOn ZNRF3-HA H1703 cells was analyzed upon siRNA knockdown of <italic>MET</italic>. Cells were treated with HGF for 2 hr before harvest. Lysates were pulled down with anti-HA antibody or control IgG and subjected to immunoblot analysis using the indicated antibodies. Data show a representative result from two independent experiments with similar outcome. (<bold>C</bold>) HGF promotes the interaction of endogenous MET with ZNRF3. Co-IP analysis in TetOn ZNRF3-HA H1703 cells upon HGF treatment. Lysates were pulled down anti-HA antibody or control IgG and subjected to immunoblot analysis. Data show a representative result from two independent experiments with similar outcome. (<bold>D</bold>) HGF promotes tyrosine phosphorylation of the 4Y motif. Analysis of tyrosine phosphorylation of ZNRF3-HA (WT) or ZNRF3(Δ4Y)-HA in H1703 cells upon HGF treatment. Lysates were pulled down with anti-HA antibody or control IgG and subjected to immunoblot analysis. Data show a representative result from two independent experiments with similar outcome. (<bold>E</bold>) Model: HGF-MET phosphorylates 4Y motif on ZNRF3. Crizotinib blocks the 4Y phosphorylation by HGF. Created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">Biorender.com</ext-link>. Source files of all blots used in this figure are available in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Uncropped immunoblot images for <xref ref-type="fig" rid="fig3">Figure 3A–D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-70885-fig3-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70885-fig3-v2.tif"/></fig></sec><sec id="s2-3"><title>HGF-MET signalling stabilizes ZNRF3 at the cell surface</title><p>We previously showed that the unphosphorylated 4Y motif is an endocytic signal for ZNRF3. Depletion of PTPRK increases ZNRF3 levels at the cell surface because phosphatase inhibition allows phosphorylation to accumulate and mask the endocytic motif (<xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref>). This finding raised the possibility that HGF-MET signaling stabilizes cell surface ZNRF3, while MET inhibition leads to ZNRF3 internalization. To test these predictions we performed cell surface biotinylation assays and monitored ZNRF3. To antagonize MET signaling, we employed Crizotinib and MET siRNA, both of which reduced cell surface levels of ZNRF3 (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). In contrast, neither the FAK inhibitor TAE226 nor the SFK inhibitor Dasatinib changed cell surface ZNRF3 levels (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A, B</xref>). Conversely, HGF treatment increased ZNRF3 surface levels in a time-dependent manner, plateauing after ~45 min (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). We conclude that HGF-MET signaling stabilizes ZNRF3 at the cell surface consistent with a role in phosphorylating and masking the endocytic 4Y motif (<xref ref-type="fig" rid="fig4">Figure 4D–E</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>HGF-MET signaling stabilizes ZNRF3 at the cell surface.</title><p>(<bold>A–B</bold>) Cell surface biotinylation assay of ZNRF3 in TetOn ZNRF3-HA H1703 cells upon Crizotinib treatment (<bold>A</bold>) or siRNA knockdown of <italic>MET</italic> (<bold>B</bold>). Cells were treated with Crizotinib (<bold>A</bold>) overnight before harvest. After labeling surface proteins with biotin, lysates were pulled down with streptavidin beads and subjected to immunoblot analysis. Transferrin receptor (TfR) or Insulin receptor beta (IRβ) was used as a loading control for avidin pulldown. Tubulin was used as a loading control for total cell lysate (Input). Data show a representative result from two independent experiments with similar outcome. (<bold>C</bold>) HGF stabilizes cell surface ZNRF3 within 45 min. Cell surface biotinylation assay in TetOn ZNRF3-HA H1703 cells upon HGF treatment for the indicated time. After labeling surface protein with biotin, lysates were pulled down with streptavidin beads and subjected to immunoblot analysis. Transferrin receptor (TfR) was used as loading control for avidin pulldown. Tubulin was used as loading control for total cell lysate (Input). Data show a representative result from two independent experiments with similar outcome. (<bold>D–E</bold>) Model: In the absence of HGF-MET signaling (<bold>D</bold>), unphosphorylated 4Y motif promotes endocytosis of ZNRF3. In the presence of HGF-MET signaling (<bold>E</bold>), activated MET phosphorylates and masks the endocytic 4Y motif, stabilizing ZNRF3 at the cell surface. Created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">Biorender.com</ext-link>. Source files of all blots used in this figure are available in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Uncropped immunoblot images for <xref ref-type="fig" rid="fig4">Figure 4A–C</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-70885-fig4-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70885-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Surface ZNRF3 is not changed by FAK or SFKs inhibitor.</title><p>(<bold>A–B</bold>) FAK or SFK inhibitor does not affect ZNRF3 cell surface levels. Cell surface biotinylation assay in TetOn ZNRF3-HA H1703 cells upon TAE226 (FAK inhibitor) (<bold>A</bold>) or Dasatinib (SFK inhibitor) (<bold>B</bold>) treatment overnight. After labeling surface proteins with biotin, lysates were pulled down with streptavidin beads and subjected to immunoblot analysis. Transferrin receptor (TfR) or Insulin receptor beta (IRβ) was used as loading control for avidin pulldown. Tubulin was used as loading control for total cell lysate (Input). Data show a representative result from two independent experiments with similar outcome. Source files of all blots used in this figure are available in <xref ref-type="supplementary-material" rid="fig4s1sdata1">Figure 4—figure supplement 1—source data 1</xref>.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Uncropped immunoblot images for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–B</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-70885-fig4-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70885-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>HGF-MET signaling stabilizes Wnt receptors by counteracting ZNRF3 function</title><p>Endocytosis of ZNRF3 driven via the 4Y motif is required to induce Wnt receptor internalization and degradation (<xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref>). Hence, 4Y phosphorylation by HGF-MET signaling may serve to counteract Wnt receptor clearance. To analyze if HGF prevents ZNRF3-mediated FZD degradation, we co-transfected FZD5 and ZNRF3 and monitored FZD5 upon HGF treatment in H1703 cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). FZD5 shows a lower band on immunoblot and a set of upper bands, known to correspond to immature and mature receptor protein, respectively. Overexpression of ZNRF3 reduced mature FZD5 levels as previously reported (<xref ref-type="bibr" rid="bib28">Hao et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Koo et al., 2012</xref>; <xref ref-type="bibr" rid="bib23">Giebel et al., 2021</xref>) (compare lanes 1 and 2). HGF reversed this reduction after 90 min treatment (lanes 7–8). We tested if the ability of HGF to stabilize FZD5 against ZNRF3 depends on the 4Y motif. Strikingly, HGF treatment rescued reduced FZD5 levels in Wt ZNRF3- but hardly in ZNRF3(∆4Y) transfected cells (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>HGF increases Wnt receptor levels by counteracting ZNRF3 function.</title><p>(<bold>A</bold>) HGF protects mature FZD5 against ZNRF3. Immunoblot analysis of V5-FZD5 in H1703 cells with ZNRF3-HA transfection upon HGF treatment as indicated. ma, im: Mature and immature forms of V5-FZD5, respectively. Rescue of ZNRF3-reduced FZD5 levels by HGF was quantified by normalizing V5-FZD5 to ERK, setting V5-FZD5 in lanes 1 and 2 to 100- and 0%, respectively, and calculating HGF-rescued levels of V5-FZD5 relative to this scale. Data show a representative result from two independent experiments with similar outcome. (<bold>B</bold>) HGF stabilizes mature FZD5 in presence of ZNRF3 but not ZNRF3(Δ4Y). Immunoblot analysis of V5-FZD5 in H1703 cells with ZNRF3-HA or ZNRF3(Δ4Y)-HA transfection upon HGF treatment as indicated. ma, im: Mature and immature forms of V5-FZD5, respectively. Data show a representative result from two independent experiments with similar outcome. (<bold>C</bold>) HGF stabilizes LRP6 levels in a ZNRF3/RNF43-dependent manner. Immunoblot of total LRP6 protein in H1703 cells upon HGF treatment without or with si<italic>ZNRF3</italic>/<italic>RNF43</italic> knockdown as indicated. ma, im: Mature and immature form of LRP6, respectively. (<bold>D</bold>) HGF enhances β-catenin levels upon Wnt3a stimulation. Immunoblot analysis of cytosolic (saponin-extracted) β-catenin in H1703 cells treated overnight as indicated. Ratio, relative levels of β-catenin normalized to ERK1/2. Data show a representative result from three independent experiments with similar outcome. (<bold>E</bold>) HGF enhances β-catenin levels upon Wnt3a stimulation. Immunofluorescence microscopy (IF) showing nuclear and cytosolic β-catenin in H1703 cells. Cells were treated overnight as indicated. Top, representative IF images. Bottom, quantification of β-catenin (Mean ± SD, ***p˂0.001, student t-test, MFI: Mean fluorescence intensity). (<bold>F</bold>) Model for how the phospho-regulated 4Y motif acts as a molecular rheostat for ZNRF3 endocytosis in Wnt signaling. MET phosphorylates and PTPRK dephosphorylates the 4Y motif, which attenuates or promotes ZNRF3 endocytosis to activate or inhibit Wnt signaling, respectively. Source files of all blots used in this figure are available in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>. A source file of densitometric analysis for Figure 5 (<bold>A and D</bold>) is available in <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Uncropped immunoblot images for <xref ref-type="fig" rid="fig5">Figure 5A–D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-70885-fig5-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Densitometric analysis of immunoblots for <xref ref-type="fig" rid="fig5">Figure 5A and D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70885-fig5-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70885-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>RSPO and HGF synergize to increase Wnt signaling.</title><p>(<bold>A</bold>) HGF-MET stabilizes LRP6 levels in a ZNRF3/RNF43-dependent manner in H3122 cells. Immunoblot of total LRP6 protein in H3122 cells upon Crizotinib treatment without or with si<italic>ZNRF3</italic>/<italic>RNF43</italic> knockdown as indicated. Ratio, relative levels of LRP6 normalized to Tubulin. Data show a representative result from two independent experiments with similar outcome. (<bold>B–C</bold>) HGF-enhanced β-catenin levels upon Wnt3a stimulation requires MET (<bold>B</bold>) and ZNRF3/RNF43 (<bold>C</bold>). Immunoblot analysis of cytosolic β-catenin in H1703 cells upon treatment overnight with or without si<italic>MET</italic> or si<italic>ZNRF3</italic>/<italic>RNF43</italic> knockdown as indicated. Ratio, relative levels of β-catenin normalized to GAPDH. Data show a representative result from two independent experiments with similar outcome. (<bold>D</bold>) HGF synergizes with RSPO on β-catenin accumulation upon Wnt3a stimulation. Immunoblot analysis of cytosolic β-catenin in H1703 cells upon treatment of Wnt3a, HGF and/or RSPO3 for 2 hr as indicated. Ratio, relative levels of β-catenin normalized to GAPDH. Data show a representative result from three independent experiments with similar outcome. Source files of all blots used in this figure are available in <xref ref-type="supplementary-material" rid="fig5s1sdata1">Figure 5—figure supplement 1—source data 1</xref>. A source file of all densitometric analysis in this figure is available in <xref ref-type="supplementary-material" rid="fig5s1sdata2">Figure 5—figure supplement 1—source data 2</xref>.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Uncropped immunoblot images for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-70885-fig5-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Densitometric analysis of immunoblots for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70885-fig5-figsupp1-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70885-fig5-figsupp1-v2.tif"/></fig></fig-group><p>To test if HGF-MET signaling also stabilizes the Wnt coreceptor LRP6, we analyzed total LRP6 by immunoblot, which also shows both upper and lower bands, known to correspond to mature post-Golgi and immature LRP6 forms, respectively. HGF specifically increased mature LRP6 levels within 1 hr treatment, and this increase by HGF was drastically abolished by si<italic>ZNRF3</italic>/<italic>RNF43</italic> treatment, which constitutively increased LRP6 levels (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). We tested an alternative lung adenocarcinoma cell line, H3122, and inhibiting MET with Crizotinib reduced mature LRP6, an effect that was almost abolished when ZNRF3/RNF43 where siRNA-inhibited (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Of note, despite the fact that it does not contain any obvious endocytic Tyr motifs, we also knocked down RNF43 in the above experiments, because ZNRF3 and RNF43 can heterodimerize (<xref ref-type="bibr" rid="bib70">Yu et al., 2020</xref>). Taken together the results support that MET signaling is necessary and sufficient for LRP6 regulation via ZNRF3 and in multiple lung cancer cell lines.</p><p>Finally, we analyzed if HGF treatment also induces downstream Wnt/β-catenin signaling by monitoring β-catenin accumulation upon Wnt3a treatment. Consistently, combined HGF and Wnt3a treatment synergized to induce β-catenin accumulation (<xref ref-type="fig" rid="fig5">Figure 5D–E</xref>). Moreover, the HGF effect was MET- and ZNRF3/RNF43 dependent (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B, C</xref>), confirming that HGF-MET promotes Wnt signaling via ZNRF3/RNF43.</p><p>Our findings suggest that HGF resembles the role of R-spondin in Wnt signaling, which also regulate ZNRF3 endocytosis, albeit by a different mechanism (<xref ref-type="bibr" rid="bib29">Hao et al., 2016</xref>). We therefore asked if HGF and RSPO3 cooperate in Wnt signaling. We treated cells with a sub-optimal dose of Wnt3a and added HGF or RSPO3 alone or in combination and then monitored β-catenin accumulation. Interestingly, HGF and RSPO3 strongly synergized in inducing β-catenin accumulation (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>), suggesting that they act non-redundantly.</p><p>Taken together, these results support a model whereby the ZNRF3 4Y motif is a phospho-regulated molecular rheostat of endocytosis: HGF-MET signaling impairs ZNRF3 function via phosphorylating and masking its endocytic 4Y motif, leading to accumulation of Wnt receptors and enhanced Wnt signalling, which is opposed by PTPRK (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>MET phosphorylation tunes ZNRF3 trafficking and function</title><p>Through in silico analysis combined with kinase inhibitor screening we identified the proto-oncogene MET as a receptor tyrosine kinase that phosphorylates the endocytic 4Y motif of ZNRF3. We further show that HGF induces the MET-ZNRF3 interaction and tyrosine phosphorylation of the 4Y motif, thereby attenuating ZNRF3 endocytosis and Wnt receptor degradation. Together with our previous report that PTPRK is a 4Y phosphatase (<xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref>), the results argue for a model whereby phosphorylation/dephosphorylation of its 4Y endocytic motif functions as a rheostat that tunes ZNRF3 function and Wnt signalling at the receptor level (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</p><p>Several lines of evidence support that MET directly phosphorylates ZNRF3: the phosphorylated 4Y motif conforms to a MET consensus phosphorylation site, MET is both necessary and sufficient for ZNRF3 phosphorylation, HGF stimulates ZNRF3 phosphorylation, and MET binds and phosphorylates ZNRF3 in a HGF-dependent manner. The fact that HGF stimulates ZNRF3 binding suggests that MET dimerization or autophosphorylation is important for their interaction. Indeed, MET is known to complex with a remarkably diverse set of other transmembrane proteins, notably cell adhesion molecules and other RTKs, thereby acting as a hub for signal integration and amplification (<xref ref-type="bibr" rid="bib17">Crepaldi et al., 1997</xref>; <xref ref-type="bibr" rid="bib21">Follenzi et al., 2000</xref>; <xref ref-type="bibr" rid="bib36">Jo et al., 2000</xref>; <xref ref-type="bibr" rid="bib65">Trusolino et al., 2001</xref>; <xref ref-type="bibr" rid="bib24">Giordano et al., 2002</xref>; <xref ref-type="bibr" rid="bib52">Orian-Rousseau et al., 2002</xref>; <xref ref-type="bibr" rid="bib63">Tanizaki et al., 2011</xref>).</p><p>It is likely that MET is not the only 4Y kinase since in early <italic>Xenopus</italic> embryos, ZNRF3 dephosphorylation by PTPRK plays a role in Spemann organizer patterning at a stage that precedes significant zygotic expression of <italic>Xenopus</italic> Met (<xref ref-type="bibr" rid="bib39">Koibuchi et al., 2004</xref>). Additional 4Y kinases besides MET may also explain while we failed to observe a role for MET in HEK29T cells (data not shown). While we found that SRC is not a 4Y kinase, it nevertheless phosphorylates ZNRF3 and our preliminary data suggest that it may inhibit Wnt signaling (data not shown).</p><p>Autophosphorylation of the MET kinase domain at Tyr1234/1235 is critical for kinase activation and in vitro, a Tyr1235 phosphopeptide is dephosphorylated by several PTPRK-like phosphatases (<xref ref-type="bibr" rid="bib5">Barr et al., 2009</xref>). Moreover, in HEK293 cells PTPRJ/DEP-1 dephosphorylates MET phospho-sites required for adapter protein binding (<xref ref-type="bibr" rid="bib53">Palka et al., 2003</xref>). Since both MET and PTPRK bind ZNRF3, it will be interesting to explore if all three proteins form a ternary complex in which MET kinase-PTPRK phosphatase cross regulate each other.</p><p>Regarding HGF vs. R-spondin function toward ZNRF3, both are secreted proteins that antagonize this E3 ubiquitin ligase by regulating its endocytosis. However, they do so in an opposite manner: R-spondins bind ZNRF3 in conjunction with LGR4 and co-internalize the complex to remove ZNRF3, thereby de-repressing Wnt receptors (<xref ref-type="bibr" rid="bib11">Carmon et al., 2011</xref>; <xref ref-type="bibr" rid="bib19">de Lau et al., 2011</xref>; <xref ref-type="bibr" rid="bib25">Glinka et al., 2011</xref>; <xref ref-type="bibr" rid="bib28">Hao et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Koo et al., 2012</xref>). HGF does the opposite: it prevents ZNRF3 co-internalization of Wnt receptors by inducing ZNRF3-MET association and 4Y phosphorylation. How can either promoting or impairing endocytosis both inhibit ZNRF3? This apparent paradox may be due to HGF-MET and R-spondins targeting either distinct ZNRF3 surface complexes or different endocytic routes. HGF and RSPO3 strongly synergized in inducing β-catenin accumulation. Relatedly, since MET binds ZNRF3, it will be interesting to test if R-spondins might co-internalize and reduce MET levels at the cell surface. The observation that HGF and RSPO3 strongly synergize in inducing β-catenin accumulation supports that they target distinct ZNRF3 pools and raises the possibility that HGF may be useful in growing Wnt-dependent organoids.</p></sec><sec id="s3-2"><title>Cross-talk between MET and Wnt signalling</title><p>We show that the net effect of HGF-MET signaling is to stabilize Wnt receptors and β-catenin. This conclusion is in keeping with other observations that MET activates Wnt signaling by signal cross-talk at entry points distinct from ZNRF3. HGF-MET signaling in renal cells stimulates GSK3-mediated LRP6 phosphorylation to promote Wnt signaling (<xref ref-type="bibr" rid="bib48">Monga et al., 2002</xref>; <xref ref-type="bibr" rid="bib41">Koraishy et al., 2014</xref>). HGF-AKT signaling was shown to decrease GSK3 activity and increase β-catenin levels (<xref ref-type="bibr" rid="bib54">Papkoff and Aikawa, 1998</xref>; <xref ref-type="bibr" rid="bib34">Ishibe et al., 2006</xref>). MET can also associate with- and phosphorylate β-catenin, promoting its nuclear translocation and Wnt signaling (<xref ref-type="bibr" rid="bib48">Monga et al., 2002</xref>; <xref ref-type="bibr" rid="bib4">Apte et al., 2006</xref>). Furthermore, HGF signaling up-regulates Wnt ligands, integrins, and LEF1 to control downstream Wnt target gene activation (<xref ref-type="bibr" rid="bib32">Huang et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Chaudhary et al., 2019</xref>). However, in H1703 cells such downstream-acting mechanisms that bypass Wnts may not be involved since without Wnt3a, HGF did not induce β-catenin accumulation and because HGF-enhanced Wnt signaling was abolished by si<italic>ZNRF3/RNF43</italic> treatment (<xref ref-type="fig" rid="fig5">Figure 5D–E</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>).</p><p>ZNRF3 is a general inhibitor of Wnt receptors of both the LRP6 and FZD family (<xref ref-type="bibr" rid="bib29">Hao et al., 2016</xref>). In addition, ZNRF3 was recently shown to inhibit BMPR1A-BMP4 signaling (<xref ref-type="bibr" rid="bib43">Lee et al., 2020</xref>). This suggests that MET inhibiting ZNRF3 may not only upregulate canonical Wnt signaling but also cross-talk with other FZD-dependent pathways such as Wnt/STOP (<xref ref-type="bibr" rid="bib61">Taelman et al., 2010</xref>; <xref ref-type="bibr" rid="bib1">Acebron et al., 2014</xref>), Wnt/PCP, and Wnt/Ca2+ (<xref ref-type="bibr" rid="bib46">Miller et al., 1999</xref>; <xref ref-type="bibr" rid="bib28">Hao et al., 2012</xref>; <xref ref-type="bibr" rid="bib67">Tsukiyama et al., 2015</xref>), as well as BMPR1A-BMP4 signaling. The reported HGF-induced hyperactivation of BMP-SMAD signaling would be consistent with this possibility (<xref ref-type="bibr" rid="bib2">Addante et al., 2020</xref>).</p><p>The cross-talk between MET and Wnt signaling is cell-biologically intriguing because of their shared property to stimulate cell proliferation, anti-apoptosis, angiogenesis, and invasive behavior (<xref ref-type="bibr" rid="bib10">Breuhahn et al., 2006</xref>; <xref ref-type="bibr" rid="bib26">Gonzalez and Medici, 2014</xref>). For example, both pathways induce a master regulator of invasion, <italic>snail</italic> (<xref ref-type="bibr" rid="bib57">Saint-Jeannet et al., 1997</xref>; <xref ref-type="bibr" rid="bib27">Grotegut et al., 2006</xref>). MET- and Wnt pathway activation are also both prominently involved in colorectal cancer (CRC) progression (<xref ref-type="bibr" rid="bib9">Bradley et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Schatoff et al., 2017</xref>). While the majority of Wnt-pathway-dependent tumors are caused by mutations in APC (adenomatous polyposis coli) that lead to ligand-receptor independent signaling, there is a class of tumors that requires Wnt-receptor signaling and displays distinct molecular pathogenesis, morphology, and prognosis (<xref ref-type="bibr" rid="bib38">Kleeman and Leedham, 2020</xref>). Our results suggest that therapy of this subclass of tumors may benefit from combined MET and Wnt inhibitor treatment by promoting ZNRF3 trafficking and Wnt receptor clearance.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">MET</td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">NM_000245</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">SRC</td><td align="left" valign="bottom">Gary DavidsonPMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25391905/">25391905</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">PTK2</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">AAH35404.1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">H1703</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-5889RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_1490">CVCL_1490</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">H3122</td><td align="left" valign="bottom">Cellosaurus</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_5160">CVCL_5160</ext-link></td><td align="left" valign="bottom">Prof. Dr. Rocio Sotillo</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="char" char="." valign="bottom">293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3216RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0063">CVCL_0063</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">H1703 TetOn ZNRF3-HA</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Generated from H1703</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-MET (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell signaling</td><td align="left" valign="bottom">8198T RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10858224">AB_10858224</ext-link></td><td align="left" valign="bottom">WB (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-MET (Y1234/1235; Rabbit monoclonal)</td><td align="left" valign="bottom">Cell signaling</td><td align="left" valign="bottom">3077T RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2143884">AB_2143884</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-α-Tubulin (Mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">T5168 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_477579">AB_477579</ext-link></td><td align="left" valign="bottom">WB (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-SRC (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell signaling</td><td align="left" valign="bottom">2,123 S RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2106047">AB_2106047</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho Src Family (Y416; Rabbit monoclonal)</td><td align="left" valign="bottom">Cell signaling</td><td align="left" valign="bottom">2,101 S RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331697">AB_331697</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Insulin receptor beta (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell signaling</td><td align="left" valign="bottom">3025T RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2280448">AB_2280448</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell signaling</td><td align="left" valign="bottom">2,118 LRRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_561053">AB_561053</ext-link></td><td align="left" valign="bottom">WB (1:10000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-β-catenin (mouse monoclonal)</td><td align="left" valign="bottom">BD bioscience</td><td align="left" valign="bottom">610154 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_397555">AB_397555</ext-link></td><td align="left" valign="bottom">WB (1:5000)IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse Alexa 488 (goat polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">A11029 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_138404">AB_138404</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">siRNA to human MET (SMARTpool)</td><td align="left" valign="bottom">Horizon discovery</td><td align="left" valign="bottom">M-003156-02-0005</td><td align="char" char="." valign="bottom">25 nM</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">siRNA to human ZNRF3 (SMARTpool)</td><td align="left" valign="bottom">Horizon discovery <break/><xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref><break/></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">siRNA to human RNF43 (SMARTpool)</td><td align="left" valign="bottom">Horizon discovery <break/><xref ref-type="bibr" rid="bib12">Chang et al., 2020</xref><break/></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pDONR223-MET</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Kit #1000000014Plasmid #23,889</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pDONR223-PTK2</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Kit #1000000014Plasmid #23,902</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pDEST-Myc-C-term</td><td align="left" valign="bottom">DKFZ Vector repository</td><td align="left" valign="bottom">MYC-C</td><td align="left" valign="bottom">Source: Stefan Pusch, University Heidelberg</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pDEST-Myc-N-term</td><td align="left" valign="bottom">DKFZ Vector repository</td><td align="left" valign="bottom">MYC-N</td><td align="left" valign="bottom">Source: Stefan Pusch, University Heidelberg</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pDEST-hSRC</td><td align="left" valign="bottom">Gary Davidson PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25391905/">25391905</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant human HGF</td><td align="left" valign="bottom">Peprotech</td><td align="char" char="ndash" valign="bottom">100–39 H</td><td align="char" char="." valign="bottom">50 ng/ml</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Kinase Screening Library (96well)</td><td align="left" valign="bottom">Cayman chemical</td><td align="char" char="." valign="bottom">10505</td><td align="char" char="." valign="bottom">500 nM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Crizotinib</td><td align="left" valign="bottom">Cayman chemical</td><td align="char" char="." valign="bottom">12087</td><td align="char" char="." valign="bottom">500 nM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dasatinib</td><td align="left" valign="bottom">Cayman chemical</td><td align="char" char="." valign="bottom">11498</td><td align="char" char="." valign="bottom">500 nM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TAE226</td><td align="left" valign="bottom">Cayman chemical</td><td align="char" char="." valign="bottom">17685</td><td align="char" char="." valign="bottom">500 nM</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture</title><p>H1703 cells (ATCC) and H3122 (Cellosaurus) were maintained in RPMI with 10 % FBS, supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate and penicillin/streptomycin. HEK293T cells (ATCC) were maintained in DMEM with 10 % FBS, supplemented with 2 ml L-glutamine and 1 mM penicillin/streptomycin. Cell identity was authenticated in ATCC based on STR profiling. Regular mycoplasma tests confirmed that both cell lines were negative for mycoplasma contamination.</p></sec><sec id="s4-2"><title>Cell transfection and treatment</title><p>For measuring pTyr-ZNRF3 upon transient DNA transfection, HEK293T or H1703 cells were grown to ~40 % confluency and transfected using X-tremeGENE9 (Roche, Basel, Switzerland) or Lipofectamine 3000 (Invitrogen, Carlsbad, CA), respectively. After 24 hr, cells were treated with 20 nM bafilomycin (Calbiochem, San Diego, CA) for 24 hr before harvest. For monitoring V5-FZD5, H1703 cells were transfected using Lipofectamine 3000 for 48 hr then treated with 50 ng/ml recombinant human HGF (Peprotech, Rocky Hill, NJ) as indicated. For measuring pTyr-ZNRF3 in TetOn ZNRF3-HA H1703 cells, cells were transfected with 25 nM of each siRNA using DharmaFECT1 (Horizon discovery, Cambridge, UK) reagent. After 24 hr, 200 ng/ml Doxycycline was added to induce ZNRF3 expression. On the following day, cells were treated with 20 nM bafilomycin for 24 hr before harvest. Where indicated, 100 ng/ml recombinant human HGF was added for 2 hr before harvest unless indicated otherwise. For monitoring MET binding to ZNRF3 using TetOn ZNRF3-HA H1703 cells, ZNRF3 was induced for 48 hr with 200 ng/ml doxycycline, and then cells were treated with 100 ng/ml recombinant human HGF as indicated. To monitor LRP6 level in H1703 or H3122 cells, 48 hr after siRNA transfection, 100 ng/ml human HGF was treated as indicated or 100 nM Crizotinib was added overnight before harvest. To measure cytosolic β-catenin, 20 % Wnt3a conditioned media and/or 100 ng/ml human HGF were added overnight before harvest. In <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>, 5% Wnt3a, 1 % RSPO3 conditioned media and/or 100 ng/ml human HGF were added 2 hr before harvest.</p></sec><sec id="s4-3"><title>Expression constructs</title><p>MET construct tagged with MYC at the C-terminus (pDEST-MET-MYC) was generated by Gateway cloning by inserting MET ORF (Open reading frame) from pDonr223-MET (Addgene; #23889) into pDEST-MYC(C-term) (DKFZ vector repository) FAK construct tagged with MYC at the N-terminus (pDEST-MYC-FAK)was generated analogously using FAK ORF from pDonr223-PTK2 (Addgene; #23902) and pDEST-MYC(N-term) (DKFZ vector repository). Constructs were validated by sequencing. pDEST-hSRC was kindly provided by Gary Davidson (<xref ref-type="bibr" rid="bib14">Chen et al., 2014</xref>).</p></sec><sec id="s4-4"><title>Immunoblot and immunoprecipitation</title><p>To isolate total cell lysates, cells were harvested in cold PBS and lysed with Triton lysis buffer (20 mM Tris-Cl, pH 7.5, 1 % Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM β-glycerophosphate, 2.5 mM sodium pyrophosphate, 1 mM Na-orthovanadate) supplemented with complete protease inhibitor cocktail (Roche, Basel, Switzerland). To obtain cytosolic fractions, cells were lysed with Saponin lysis buffer (20 mM Tris-Cl, pH 7.5, 0.05 % Saponin, 1 mM MgCl<sub>2</sub>, 1 mM Na-orthovanadate) supplemented with complete protease inhibitor cocktail (Roche, Basel, Switzerland). Lysates were cleared by centrifugation, and a Bradford assay was performed to measure the protein concentration. For immunoblot, 30 μg of lysates were mixed with NuPage LDS sample buffer containing 50 mM DTT and heated at 70 °C for 10 min. For <xref ref-type="fig" rid="fig5">Figure 5A–B</xref>, samples were not heated to prevent aggregation of FZD5 protein.</p><p>For co-immunoprecipitation or pull-down assays, 300–800 μg of total cell lysates were precleared with 10 μl of Protein A/G Plus Agarose (Santacruz Biotechnologies, Santacruz, CA) on a rotator at 4 °C for 1 hr. Precleared lysates were incubated with 20 μl of A/G Plus Agarose with anti-HA (1867423; Roche, Basel, Switzerland) on a rotator at 4 °C for 4 hr. Immunoprecipitated proteins were washed with Triton lysis buffer four times and mixed with NuPage LDS sample buffer containing 50 mM DTT, followed by heating at 70 °C for 10 min. Samples were subjected to SDS-PAGE, transferred to nitrocellulose membrane, and blocked with 5 % BSA in TBST (10 mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.05 % Tween-20). Primary antibodies in blocking buffer were applied overnight at 4 °C, and incubation of secondary antibodies was carried out at RT for 1 hr. Immunoblots were developed with SuperSignal West pico ECL (Thermo Scientific, Waltham, MA) and analyzed using a LAS-3000 (Fujifilm, Tokyo, Japan). Densitometry analyses were done with Multi-gauge software (Fujifilm, Tokyo, Japan). Antibody information is listed in key resource table.</p></sec><sec id="s4-5"><title>Kinase inhibitor screening</title><p>Human ZNRF3 was analyzed with the kinase prediction online tool, GPS 3.0 (<ext-link ext-link-type="uri" xlink:href="http://gps.biocuckoo.cn/index.php">http://gps.biocuckoo.cn/index.php</ext-link>, Wuhan, China) to select candidates for 4Y kinase screening. Additional PTK candidates were selected based on plasma membrane or cortical localization (<xref ref-type="bibr" rid="bib59">Shuai and Liu, 2003</xref>; <xref ref-type="bibr" rid="bib33">Ingley, 2008</xref>; <xref ref-type="bibr" rid="bib47">Mocsai et al., 2010</xref>). For screening, TetOn ZNRF3-HA H1703 cells were induced with doxycycline (DOX) (200 ng/ml). After 24 hr, tyrosine kinase inhibitors (500 nM; stocks in DMSO) from a Kinase screening library (Cayman, Ann Arbor, MI) were added together with bafilomycin (20 nM) for additional 24 hr before harvest. DMSO was used as a control. Cells were lysed with Triton lysis buffer (20 mM Tris-Cl, pH 7.5, 1 % Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM β-glycerophosphate, 2,5 mM sodium pyrophosphate, 1 mM Na- orthovanadate) supplemented with complete protease inhibitor cocktail (Roche, Basel, Switzerland), followed by centrifugation and samples were subjected to SDS-PAGE analysis and immunoblot for pan-phosphotyrosine (pTyr-ZNRF3), HA (total ZNRF3) and α-tubulin. For the quantitative analysis, background signals (cells without Dox treatment) were subtracted from phospho-tyrosine signals before normalizing to total ZNRF3. Dot graph was generated with Graphpad (Prism) using average pTyr signal and p-value (student t-test).</p></sec><sec id="s4-6"><title>Cell surface biotinylation assay</title><p>TetOn ZNRF3-HA H1703 cells were induced with doxycycline (200 ng/ml). Where indicated, cells were transfected with siRNA for 72 hr or treated with chemical inhibitors (500 nM) for 24 hr and washed three times with cold PBS. Surface proteins were biotinylated with 0.25 mg/ml sulfo-NHS-LC-LC-Biotin (Thermo scientific, Waltham, MA) at 4 °C for 30 min. For non-biotinylated control, PBS was added. The reaction was quenched by washing 3 times with 10 mM monoethanolamine and cells were harvested and lysed with Triton lysis buffer. 200–300 μg of lysate was incubated with 10 μl streptavidin agarose (Thermo scientific, Waltham, MA) to pull-down biotinylated surface proteins, and precipitated proteins were subjected to immunoblot analysis as indicated.</p></sec><sec id="s4-7"><title>Immunofluorescence microscopy</title><p>Cells were grown on coverslips in 12-well plates, followed by Wnt3a and/or HGF treatment overnight. Cells were fixed in 4 % PFA for 10 min, permeabilized and blocked (PBS, 0.1 % Tween, 4 % normal goat serum) for 1 hr. β-catenin antibodies (1:500) were incubated overnight at 4 °C, and goat-anti mouse Alexa 488 (1:500) was applied for 1 hr at room temperature. Coverslips were mounted with Fluoromount-G. Images were obtained using LSM 700 (Zeiss). Quantification was done using Image J.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Validation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Validation</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Funding acquisition, Project administration, Supervision, Writing - original draft, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-70885-transrepform1-v2.docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Data of Inhibitor screen for ZNRF3 4Y kinases.</title><p>Table of inhibitor screen results. The table includes the name of inhibitors, relative pTyr-ZNRF3 from two screens, average, and p-value.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70885-supp1-v2.xlsx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting file; Source Data files have been provided for every figure.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank F Cong (Novartis) for providing the ZNRF3 constructs; G Davidson for providing the SRC construct and R Sotillo (DKFZ) for providing H3122 cells. We thank expert technical support by the DKFZ core facility for light microscopy. We thank A Hirth for help with BioRender and thank H Lee for illustrations. This work was funded by the Deutsche Forschungsgemein-schaft (DFG, German Research Foundation) – SFB 1324/2, B01.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acebron</surname><given-names>SP</given-names></name><name><surname>Karaulanov</surname><given-names>E</given-names></name><name><surname>Berger</surname><given-names>BS</given-names></name><name><surname>Huang</surname><given-names>YL</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mitotic WNT signaling promotes protein stabilization and regulates cell size</article-title><source>Molecular Cell</source><volume>54</volume><fpage>663</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.04.014</pub-id><pub-id pub-id-type="pmid">24837680</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addante</surname><given-names>A</given-names></name><name><surname>Roncero</surname><given-names>C</given-names></name><name><surname>Lazcanoiturburu</surname><given-names>N</given-names></name><name><surname>Méndez</surname><given-names>R</given-names></name><name><surname>Almalé</surname><given-names>L</given-names></name><name><surname>García-Álvaro</surname><given-names>M</given-names></name><name><surname>Ten Dijke</surname><given-names>P</given-names></name><name><surname>Fabregat</surname><given-names>I</given-names></name><name><surname>Herrera</surname><given-names>B</given-names></name><name><surname>Sánchez</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A signaling crosstalk between bmp9 and HGF/C-MET regulates mouse adult liver progenitor cell survival</article-title><source>Cells</source><volume>9</volume><elocation-id>E752</elocation-id><pub-id pub-id-type="doi">10.3390/cells9030752</pub-id><pub-id pub-id-type="pmid">32204446</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthony</surname><given-names>CC</given-names></name><name><surname>Robbins</surname><given-names>DJ</given-names></name><name><surname>Ahmed</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nuclear Regulation of Wnt/β-Catenin Signaling: It’s a Complex Situation</article-title><source>Genes</source><volume>11</volume><elocation-id>E886</elocation-id><pub-id pub-id-type="doi">10.3390/genes11080886</pub-id><pub-id pub-id-type="pmid">32759724</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apte</surname><given-names>U</given-names></name><name><surname>Zeng</surname><given-names>G</given-names></name><name><surname>Muller</surname><given-names>P</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Micsenyi</surname><given-names>A</given-names></name><name><surname>Cieply</surname><given-names>B</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name><name><surname>Monga</surname><given-names>SPS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice</article-title><source>Hepatology</source><volume>44</volume><fpage>992</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1002/hep.21317</pub-id><pub-id pub-id-type="pmid">17006939</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>AJ</given-names></name><name><surname>Ugochukwu</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>WH</given-names></name><name><surname>King</surname><given-names>ON</given-names></name><name><surname>Filippakopoulos</surname><given-names>P</given-names></name><name><surname>Alfano</surname><given-names>I</given-names></name><name><surname>Savitsky</surname><given-names>P</given-names></name><name><surname>Burgess-Brown</surname><given-names>NA</given-names></name><name><surname>Muller</surname><given-names>S</given-names></name><name><surname>Knapp</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Large-scale structural analysis of the classical human protein tyrosine phosphatome</article-title><source>Cell</source><volume>136</volume><fpage>352</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.11.038</pub-id><pub-id pub-id-type="pmid">19167335</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>BS</given-names></name><name><surname>Acebron</surname><given-names>SP</given-names></name><name><surname>Herbst</surname><given-names>J</given-names></name><name><surname>Koch</surname><given-names>S</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Parkinson’s disease-associated receptor GPR37 is an ER chaperone for LRP6</article-title><source>EMBO Reports</source><volume>18</volume><fpage>712</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.15252/embr.201643585</pub-id><pub-id pub-id-type="pmid">28341812</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertotti</surname><given-names>A</given-names></name><name><surname>Bracco</surname><given-names>C</given-names></name><name><surname>Girolami</surname><given-names>F</given-names></name><name><surname>Torti</surname><given-names>D</given-names></name><name><surname>Gastaldi</surname><given-names>S</given-names></name><name><surname>Galimi</surname><given-names>F</given-names></name><name><surname>Medico</surname><given-names>E</given-names></name><name><surname>Elvin</surname><given-names>P</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name><name><surname>Trusolino</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Inhibition of SRC impairs the growth of met-addicted gastric tumors</article-title><source>Clinical Cancer Research</source><volume>16</volume><fpage>3933</fpage><lpage>3943</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0106</pub-id><pub-id pub-id-type="pmid">20628031</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifacino</surname><given-names>JS</given-names></name><name><surname>Traub</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Signals for sorting of transmembrane proteins to endosomes and lysosomes</article-title><source>Annual Review of Biochemistry</source><volume>72</volume><fpage>395</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.72.121801.161800</pub-id><pub-id pub-id-type="pmid">12651740</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>CA</given-names></name><name><surname>Salto-Tellez</surname><given-names>M</given-names></name><name><surname>Laurent-Puig</surname><given-names>P</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Rolfo</surname><given-names>C</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Khawaja</surname><given-names>HA</given-names></name><name><surname>Lawler</surname><given-names>M</given-names></name><name><surname>Johnston</surname><given-names>PG</given-names></name><name><surname>Van Schaeybroeck</surname><given-names>S</given-names></name><collab>MErCuRIC consortium</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting C-MET in gastrointestinal tumours: Rationale, opportunities and challenges</article-title><source>Nature Reviews. Clinical Oncology</source><volume>14</volume><fpage>562</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2017.40</pub-id><pub-id pub-id-type="pmid">28374784</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breuhahn</surname><given-names>K</given-names></name><name><surname>Longerich</surname><given-names>T</given-names></name><name><surname>Schirmacher</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Dysregulation of growth factor signaling in human hepatocellular carcinoma</article-title><source>Oncogene</source><volume>25</volume><fpage>3787</fpage><lpage>3800</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209556</pub-id><pub-id pub-id-type="pmid">16799620</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmon</surname><given-names>KS</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>R-spondins function as ligands of the orphan receptors lgr4 and lgr5 to regulate wnt/beta-catenin signaling</article-title><source>PNAS</source><volume>108</volume><fpage>11452</fpage><lpage>11457</lpage><pub-id pub-id-type="doi">10.1073/pnas.1106083108</pub-id><pub-id pub-id-type="pmid">21693646</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>LS</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Glinka</surname><given-names>A</given-names></name><name><surname>Reinhard</surname><given-names>C</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The tumor suppressor PTPRK promotes znrf3 internalization and is required for WNT inhibition in the Spemann organizer</article-title><source>eLife</source><volume>9</volume><elocation-id>e51248</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.51248</pub-id><pub-id pub-id-type="pmid">31934854</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhary</surname><given-names>P</given-names></name><name><surname>Malhotra</surname><given-names>SS</given-names></name><name><surname>Babu</surname><given-names>GS</given-names></name><name><surname>Sobti</surname><given-names>RC</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HGF promotes HTR-8/SVneo cell migration through activation of MAPK/PKA signaling leading to up-regulation of WNT ligands and integrins that target β-catenin</article-title><source>Molecular and Cellular Biochemistry</source><volume>453</volume><fpage>11</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s11010-018-3428-3</pub-id><pub-id pub-id-type="pmid">30136190</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Wesslowski</surname><given-names>J</given-names></name><name><surname>Hagemann</surname><given-names>AI</given-names></name><name><surname>Ramialison</surname><given-names>M</given-names></name><name><surname>Wittbrodt</surname><given-names>J</given-names></name><name><surname>Scholpp</surname><given-names>S</given-names></name><name><surname>Davidson</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tyrosine phosphorylation of LRP6 by Src and Fer inhibits Wnt/β-catenin signalling</article-title><source>EMBO Reports</source><volume>15</volume><fpage>1254</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.15252/embr.201439644</pub-id><pub-id pub-id-type="pmid">25391905</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ci</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>North</surname><given-names>BJ</given-names></name><name><surname>Inuzuka</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>SCF(beta-TRCP) E3 ubiquitin ligase targets the tumor suppressor ZNRF3 for ubiquitination and degradation</article-title><source>Protein &amp; Cell</source><volume>9</volume><fpage>879</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1007/s13238-018-0510-2</pub-id><pub-id pub-id-type="pmid">29497989</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Wnt/beta-catenin signaling and disease</article-title><source>Cell</source><volume>149</volume><fpage>1192</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.05.012</pub-id><pub-id pub-id-type="pmid">22682243</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crepaldi</surname><given-names>T</given-names></name><name><surname>Gautreau</surname><given-names>A</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name><name><surname>Louvard</surname><given-names>D</given-names></name><name><surname>Arpin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells</article-title><source>The Journal of Cell Biology</source><volume>138</volume><fpage>423</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1083/jcb.138.2.423</pub-id><pub-id pub-id-type="pmid">9230083</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruciat</surname><given-names>CM</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Secreted and transmembrane wnt inhibitors and activators</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>5</volume><elocation-id>a015081</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a015081</pub-id><pub-id pub-id-type="pmid">23085770</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lau</surname><given-names>W</given-names></name><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Low</surname><given-names>TY</given-names></name><name><surname>Koo</surname><given-names>B-K</given-names></name><name><surname>Li</surname><given-names>VSW</given-names></name><name><surname>Teunissen</surname><given-names>H</given-names></name><name><surname>Kujala</surname><given-names>P</given-names></name><name><surname>Haegebarth</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>PJ</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Stange</surname><given-names>DE</given-names></name><name><surname>van Es</surname><given-names>JE</given-names></name><name><surname>Guardavaccaro</surname><given-names>D</given-names></name><name><surname>Schasfoort</surname><given-names>RBM</given-names></name><name><surname>Mohri</surname><given-names>Y</given-names></name><name><surname>Nishimori</surname><given-names>K</given-names></name><name><surname>Mohammed</surname><given-names>S</given-names></name><name><surname>Heck</surname><given-names>AJR</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Lgr5 homologues associate with Wnt receptors and mediate r-spondin signalling</article-title><source>Nature</source><volume>476</volume><fpage>293</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1038/nature10337</pub-id><pub-id pub-id-type="pmid">21727895</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lau</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>WC</given-names></name><name><surname>Gros</surname><given-names>P</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The R-SPONDIN/LGR5/RNF43 module: Regulator of Wnt signal strength</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>305</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1101/gad.235473.113</pub-id><pub-id pub-id-type="pmid">24532711</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Follenzi</surname><given-names>A</given-names></name><name><surname>Bakovic</surname><given-names>S</given-names></name><name><surname>Gual</surname><given-names>P</given-names></name><name><surname>Stella</surname><given-names>MC</given-names></name><name><surname>Longati</surname><given-names>P</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cross-talk between the proto-oncogenes Met and Ron</article-title><source>Oncogene</source><volume>19</volume><fpage>3041</fpage><lpage>3049</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203620</pub-id><pub-id pub-id-type="pmid">10871856</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gherardi</surname><given-names>E</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name><name><surname>Birchmeier</surname><given-names>C</given-names></name><name><surname>Vande Woude</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Targeting met in cancer: Rationale and progress</article-title><source>Nature Reviews. Cancer</source><volume>12</volume><fpage>89</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nrc3205</pub-id><pub-id pub-id-type="pmid">22270953</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giebel</surname><given-names>N</given-names></name><name><surname>de Jaime-Soguero</surname><given-names>A</given-names></name><name><surname>García Del Arco</surname><given-names>A</given-names></name><name><surname>Landry</surname><given-names>JJM</given-names></name><name><surname>Tietje</surname><given-names>M</given-names></name><name><surname>Villacorta</surname><given-names>L</given-names></name><name><surname>Benes</surname><given-names>V</given-names></name><name><surname>Fernández-Sáiz</surname><given-names>V</given-names></name><name><surname>Acebrón</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>USP42 protects znrf3/rnf43 from r-spondin-dependent clearance and inhibits WNT signalling</article-title><source>EMBO Reports</source><volume>22</volume><elocation-id>e51415</elocation-id><pub-id pub-id-type="doi">10.15252/embr.202051415</pub-id><pub-id pub-id-type="pmid">33786993</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giordano</surname><given-names>S</given-names></name><name><surname>Corso</surname><given-names>S</given-names></name><name><surname>Conrotto</surname><given-names>P</given-names></name><name><surname>Artigiani</surname><given-names>S</given-names></name><name><surname>Gilestro</surname><given-names>G</given-names></name><name><surname>Barberis</surname><given-names>D</given-names></name><name><surname>Tamagnone</surname><given-names>L</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The semaphorin 4d receptor controls invasive growth by coupling with met</article-title><source>Nature Cell Biology</source><volume>4</volume><fpage>720</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/ncb843</pub-id><pub-id pub-id-type="pmid">12198496</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glinka</surname><given-names>A</given-names></name><name><surname>Dolde</surname><given-names>C</given-names></name><name><surname>Kirsch</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>YL</given-names></name><name><surname>Kazanskaya</surname><given-names>O</given-names></name><name><surname>Ingelfinger</surname><given-names>D</given-names></name><name><surname>Boutros</surname><given-names>M</given-names></name><name><surname>Cruciat</surname><given-names>CM</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>LGR4 and LGR5 are R-spondin receptors mediating Wnt/β-catenin and Wnt/PCP signalling</article-title><source>EMBO Reports</source><volume>12</volume><fpage>1055</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1038/embor.2011.175</pub-id><pub-id pub-id-type="pmid">21909076</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>DM</given-names></name><name><surname>Medici</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Signaling mechanisms of the epithelial-mesenchymal transition</article-title><source>Science Signaling</source><volume>7</volume><elocation-id>re8</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2005189</pub-id><pub-id pub-id-type="pmid">25249658</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grotegut</surname><given-names>S</given-names></name><name><surname>von Schweinitz</surname><given-names>D</given-names></name><name><surname>Christofori</surname><given-names>G</given-names></name><name><surname>Lehembre</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Hepatocyte growth factor induces cell scattering through mapk/egr-1-mediated upregulation of snail</article-title><source>The EMBO Journal</source><volume>25</volume><fpage>3534</fpage><lpage>3545</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601213</pub-id><pub-id pub-id-type="pmid">16858414</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>H-X</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Charlat</surname><given-names>O</given-names></name><name><surname>Oster</surname><given-names>E</given-names></name><name><surname>Avello</surname><given-names>M</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Mickanin</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Ruffner</surname><given-names>H</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Zamponi</surname><given-names>R</given-names></name><name><surname>Bouwmeester</surname><given-names>T</given-names></name><name><surname>Finan</surname><given-names>PM</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name><name><surname>Porter</surname><given-names>JA</given-names></name><name><surname>Serluca</surname><given-names>FC</given-names></name><name><surname>Cong</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ZNRF3 promotes wnt receptor turnover in an r-spondin-sensitive manner</article-title><source>Nature</source><volume>485</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/nature11019</pub-id><pub-id pub-id-type="pmid">22575959</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>HX</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Cong</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Control of wnt receptor turnover by r-spondin-znrf3/rnf43 signaling module and its dysregulation in cancer</article-title><source>Cancers</source><volume>8</volume><elocation-id>E54</elocation-id><pub-id pub-id-type="doi">10.3390/cancers8060054</pub-id><pub-id pub-id-type="pmid">27338477</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herynk</surname><given-names>MH</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Parikh</surname><given-names>NU</given-names></name><name><surname>Gallick</surname><given-names>GE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Activation of SRC by c-met overexpression mediates metastatic properties of colorectal carcinoma cells</article-title><source>Journal of Experimental Therapeutics &amp; Oncology</source><volume>6</volume><fpage>205</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">17552361</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>JC</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wefer</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>DeRossi</surname><given-names>C</given-names></name><name><surname>Wines</surname><given-names>ME</given-names></name><name><surname>Rosenquist</surname><given-names>T</given-names></name><name><surname>Holdener</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>MESD encodes an lrp5/6 chaperone essential for specification of mouse embryonic polarity</article-title><source>Cell</source><volume>112</volume><fpage>355</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(03)00045-x</pub-id><pub-id pub-id-type="pmid">12581525</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>FI</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Chang</surname><given-names>CN</given-names></name><name><surname>Yuan</surname><given-names>RH</given-names></name><name><surname>Jeng</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion</article-title><source>Carcinogenesis</source><volume>33</volume><fpage>1142</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgs131</pub-id><pub-id pub-id-type="pmid">22436613</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingley</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Src family kinases: regulation of their activities, levels and identification of new pathways</article-title><source>Biochimica et Biophysica Acta</source><volume>1784</volume><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2007.08.012</pub-id><pub-id pub-id-type="pmid">17905674</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishibe</surname><given-names>S</given-names></name><name><surname>Haydu</surname><given-names>JE</given-names></name><name><surname>Togawa</surname><given-names>A</given-names></name><name><surname>Marlier</surname><given-names>A</given-names></name><name><surname>Cantley</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cell confluence regulates hepatocyte growth factor-stimulated cell morphogenesis in a beta-catenin-dependent manner</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>9232</fpage><lpage>9243</lpage><pub-id pub-id-type="doi">10.1128/MCB.01312-06</pub-id><pub-id pub-id-type="pmid">17030602</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Charlat</surname><given-names>O</given-names></name><name><surname>Zamponi</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Cong</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dishevelled promotes Wnt receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases</article-title><source>Molecular Cell</source><volume>58</volume><fpage>522</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.03.015</pub-id><pub-id pub-id-type="pmid">25891077</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>M</given-names></name><name><surname>Stolz</surname><given-names>DB</given-names></name><name><surname>Esplen</surname><given-names>JE</given-names></name><name><surname>Dorko</surname><given-names>K</given-names></name><name><surname>Michalopoulos</surname><given-names>GK</given-names></name><name><surname>Strom</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>8806</fpage><lpage>8811</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.12.8806</pub-id><pub-id pub-id-type="pmid">10722725</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Jho</surname><given-names>EH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Wnt/beta-catenin signalling: from plasma membrane to nucleus</article-title><source>The Biochemical Journal</source><volume>450</volume><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1042/BJ20121284</pub-id><pub-id pub-id-type="pmid">23343194</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleeman</surname><given-names>SO</given-names></name><name><surname>Leedham</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer</article-title><source>Cancers</source><volume>12</volume><elocation-id>3355</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12113355</pub-id><pub-id pub-id-type="pmid">33202731</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koibuchi</surname><given-names>N</given-names></name><name><surname>Kaneda</surname><given-names>Y</given-names></name><name><surname>Taniyama</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name><name><surname>Morishita</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Essential role of HGF (hepatocyte growth factor) in blood formation in <italic>Xenopus</italic></article-title><source>Blood</source><volume>103</volume><fpage>3320</fpage><lpage>3325</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-02-0352</pub-id><pub-id pub-id-type="pmid">14701703</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>BK</given-names></name><name><surname>Spit</surname><given-names>M</given-names></name><name><surname>Jordens</surname><given-names>I</given-names></name><name><surname>Low</surname><given-names>TY</given-names></name><name><surname>Stange</surname><given-names>DE</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>Mohammed</surname><given-names>S</given-names></name><name><surname>Heck</surname><given-names>AJ</given-names></name><name><surname>Maurice</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors</article-title><source>Nature</source><volume>488</volume><fpage>665</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1038/nature11308</pub-id><pub-id pub-id-type="pmid">22895187</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koraishy</surname><given-names>FM</given-names></name><name><surname>Silva</surname><given-names>C</given-names></name><name><surname>Mason</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Cantley</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hepatocyte growth factor (Hgf) stimulates low density lipoprotein receptor-related protein (Lrp) 5/6 phosphorylation and promotes canonical Wnt signaling</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>14341</fpage><lpage>14350</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.563213</pub-id><pub-id pub-id-type="pmid">24692544</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubo</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Lockwood</surname><given-names>WW</given-names></name><name><surname>Valencia</surname><given-names>I</given-names></name><name><surname>Soh</surname><given-names>J</given-names></name><name><surname>Peyton</surname><given-names>M</given-names></name><name><surname>Jida</surname><given-names>M</given-names></name><name><surname>Otani</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Ouchida</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors</article-title><source>International Journal of Cancer</source><volume>124</volume><fpage>1778</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1002/ijc.24150</pub-id><pub-id pub-id-type="pmid">19117057</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Seidl</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Glinka</surname><given-names>A</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>R-spondins are BMP receptor antagonists in <italic>Xenopus</italic> early embryonic development</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5570</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19373-w</pub-id><pub-id pub-id-type="pmid">33149137</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>BT</given-names></name><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Wnt/beta-catenin signaling: components, mechanisms, and diseases</article-title><source>Developmental Cell</source><volume>17</volume><fpage>9</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2009.06.016</pub-id><pub-id pub-id-type="pmid">19619488</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>R</given-names></name><name><surname>Mambetsariev</surname><given-names>I</given-names></name><name><surname>Fricke</surname><given-names>J</given-names></name><name><surname>Chawla</surname><given-names>N</given-names></name><name><surname>Nam</surname><given-names>A</given-names></name><name><surname>Pharaon</surname><given-names>R</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>MET receptor in oncology: From biomarker to therapeutic target</article-title><source>Advances in Cancer Research</source><volume>147</volume><fpage>259</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/bs.acr.2020.04.006</pub-id><pub-id pub-id-type="pmid">32593403</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JR</given-names></name><name><surname>Hocking</surname><given-names>AM</given-names></name><name><surname>Brown</surname><given-names>JD</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mechanism and function of signal transduction by the wnt/beta-catenin and Wnt/ca2+ pathways</article-title><source>Oncogene</source><volume>18</volume><fpage>7860</fpage><lpage>7872</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203245</pub-id><pub-id pub-id-type="pmid">10630639</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mocsai</surname><given-names>A</given-names></name><name><surname>Ruland</surname><given-names>J</given-names></name><name><surname>Tybulewicz</surname><given-names>VL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The SYK tyrosine kinase: a crucial player in diverse biological functions</article-title><source>Nature Reviews. Immunology</source><volume>10</volume><fpage>387</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/nri2765</pub-id><pub-id pub-id-type="pmid">20467426</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monga</surname><given-names>SPS</given-names></name><name><surname>Mars</surname><given-names>WM</given-names></name><name><surname>Pediaditakis</surname><given-names>P</given-names></name><name><surname>Bell</surname><given-names>A</given-names></name><name><surname>Mulé</surname><given-names>K</given-names></name><name><surname>Bowen</surname><given-names>WC</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zarnegar</surname><given-names>R</given-names></name><name><surname>Michalopoulos</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Hepatocyte growth factor induces wnt-independent nuclear translocation of beta-catenin after met-beta-catenin dissociation in hepatocytes</article-title><source>Cancer Research</source><volume>62</volume><fpage>2064</fpage><lpage>2071</lpage><pub-id pub-id-type="pmid">11929826</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niehrs</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regulation of Lrp6 phosphorylation</article-title><source>Cellular and Molecular Life Sciences</source><volume>67</volume><fpage>2551</fpage><lpage>2562</lpage><pub-id pub-id-type="doi">10.1007/s00018-010-0329-3</pub-id><pub-id pub-id-type="pmid">20229235</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The complex world of WNT receptor signalling</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>13</volume><fpage>767</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1038/nrm3470</pub-id><pub-id pub-id-type="pmid">23151663</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities</article-title><source>Cell</source><volume>169</volume><fpage>985</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.016</pub-id><pub-id pub-id-type="pmid">28575679</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orian-Rousseau</surname><given-names>V</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Sleeman</surname><given-names>JP</given-names></name><name><surname>Herrlich</surname><given-names>P</given-names></name><name><surname>Ponta</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>CD44 is required for two consecutive steps in HGF/C-MET signaling</article-title><source>Genes &amp; Development</source><volume>16</volume><fpage>3074</fpage><lpage>3086</lpage><pub-id pub-id-type="doi">10.1101/gad.242602</pub-id><pub-id pub-id-type="pmid">12464636</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palka</surname><given-names>HL</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Tonks</surname><given-names>NK</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>5728</fpage><lpage>5735</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210656200</pub-id><pub-id pub-id-type="pmid">12475979</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papkoff</surname><given-names>J</given-names></name><name><surname>Aikawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>WNT-1 and HGF regulate GSK3 beta activity and beta-catenin signaling in mammary epithelial cells</article-title><source>Biochemical and Biophysical Research Communications</source><volume>247</volume><fpage>851</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1998.8888</pub-id><pub-id pub-id-type="pmid">9647782</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roush</surname><given-names>DL</given-names></name><name><surname>Gottardi</surname><given-names>CJ</given-names></name><name><surname>Naim</surname><given-names>HY</given-names></name><name><surname>Roth</surname><given-names>MG</given-names></name><name><surname>Caplan</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Tyrosine-based membrane protein sorting signals are differentially interpreted by polarized Madin-Darby canine kidney and LLC-PK1 epithelial cells</article-title><source>The Journal of Biological Chemistry</source><volume>273</volume><fpage>26862</fpage><lpage>26869</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.41.26862</pub-id><pub-id pub-id-type="pmid">9756932</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Royle</surname><given-names>SJ</given-names></name><name><surname>Qureshi</surname><given-names>OS</given-names></name><name><surname>Bobanovic</surname><given-names>LK</given-names></name><name><surname>Evans</surname><given-names>PR</given-names></name><name><surname>Owen</surname><given-names>DJ</given-names></name><name><surname>Murrell-Lagnado</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Non-canonical YXXGPhi endocytic motifs: recognition by AP2 and preferential utilization in P2X4 receptors</article-title><source>Journal of Cell Science</source><volume>118</volume><fpage>3073</fpage><lpage>3080</lpage><pub-id pub-id-type="doi">10.1242/jcs.02451</pub-id><pub-id pub-id-type="pmid">15985462</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saint-Jeannet</surname><given-names>JP</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Varmus</surname><given-names>HE</given-names></name><name><surname>Dawid</surname><given-names>IB</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Regulation of dorsal fate in the neuraxis by Wnt-1 and WNT-3A</article-title><source>PNAS</source><volume>94</volume><fpage>13713</fpage><lpage>13718</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.25.13713</pub-id><pub-id pub-id-type="pmid">9391091</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schatoff</surname><given-names>EM</given-names></name><name><surname>Leach</surname><given-names>BI</given-names></name><name><surname>Dow</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Wnt Signaling and Colorectal Cancer</article-title><source>Current Colorectal Cancer Reports</source><volume>13</volume><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1007/s11888-017-0354-9</pub-id><pub-id pub-id-type="pmid">28413363</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuai</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Regulation of JAK-STAT signalling in the immune system</article-title><source>Nature Reviews. Immunology</source><volume>3</volume><fpage>900</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1038/nri1226</pub-id><pub-id pub-id-type="pmid">14668806</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>PL</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Soriano</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Combined deficiencies of SRC, Fyn, and yes tyrosine kinases in mutant mice</article-title><source>Genes &amp; Development</source><volume>8</volume><fpage>1999</fpage><lpage>2007</lpage><pub-id pub-id-type="doi">10.1101/gad.8.17.1999</pub-id><pub-id pub-id-type="pmid">7958873</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taelman</surname><given-names>VF</given-names></name><name><surname>Dobrowolski</surname><given-names>R</given-names></name><name><surname>Plouhinec</surname><given-names>JL</given-names></name><name><surname>Fuentealba</surname><given-names>LC</given-names></name><name><surname>Vorwald</surname><given-names>PP</given-names></name><name><surname>Gumper</surname><given-names>I</given-names></name><name><surname>Sabatini</surname><given-names>DD</given-names></name><name><surname>De Robertis</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>WNT signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes</article-title><source>Cell</source><volume>143</volume><fpage>1136</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.11.034</pub-id><pub-id pub-id-type="pmid">21183076</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taher</surname><given-names>TEI</given-names></name><name><surname>Tjin</surname><given-names>EPM</given-names></name><name><surname>Beuling</surname><given-names>EA</given-names></name><name><surname>Borst</surname><given-names>J</given-names></name><name><surname>Spaargaren</surname><given-names>M</given-names></name><name><surname>Pals</surname><given-names>ST</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>C-CBL is involved in met signaling in b cells and mediates hepatocyte growth factor-induced receptor ubiquitination</article-title><source>Journal of Immunology</source><volume>169</volume><fpage>3793</fpage><lpage>3800</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.7.3793</pub-id><pub-id pub-id-type="pmid">12244174</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanizaki</surname><given-names>J</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name><name><surname>Sakai</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Differential roles of trans-phosphorylated EGFR, her2, her3, and RET as heterodimerisation partners of met in lung cancer with met amplification</article-title><source>British Journal of Cancer</source><volume>105</volume><fpage>807</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.322</pub-id><pub-id pub-id-type="pmid">21847121</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>SM</given-names></name><name><surname>Soriano</surname><given-names>P</given-names></name><name><surname>Imamoto</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Specific and redundant roles of SRC and FYN in organizing the cytoskeleton</article-title><source>Nature</source><volume>376</volume><fpage>267</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/376267a0</pub-id><pub-id pub-id-type="pmid">7617039</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trusolino</surname><given-names>L</given-names></name><name><surname>Bertotti</surname><given-names>A</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A signaling adapter function for alpha6beta4 integrin in the control of hgf-dependent invasive growth</article-title><source>Cell</source><volume>107</volume><fpage>643</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(01)00567-0</pub-id><pub-id pub-id-type="pmid">11733063</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trusolino</surname><given-names>L</given-names></name><name><surname>Bertotti</surname><given-names>A</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Met signalling: Principles and functions in development, organ regeneration and cancer</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>11</volume><fpage>834</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1038/nrm3012</pub-id><pub-id pub-id-type="pmid">21102609</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukiyama</surname><given-names>T</given-names></name><name><surname>Fukui</surname><given-names>A</given-names></name><name><surname>Terai</surname><given-names>S</given-names></name><name><surname>Fujioka</surname><given-names>Y</given-names></name><name><surname>Shinada</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>TP</given-names></name><name><surname>Ohba</surname><given-names>Y</given-names></name><name><surname>Hatakeyama</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Molecular role of RNF43 in canonical and noncanonical wnt signaling</article-title><source>Molecular and Cellular Biology</source><volume>35</volume><fpage>2007</fpage><lpage>2023</lpage><pub-id pub-id-type="doi">10.1128/MCB.00159-15</pub-id><pub-id pub-id-type="pmid">25825523</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weekes</surname><given-names>MP</given-names></name><name><surname>Antrobus</surname><given-names>R</given-names></name><name><surname>Talbot</surname><given-names>S</given-names></name><name><surname>Hör</surname><given-names>S</given-names></name><name><surname>Simecek</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Bloor</surname><given-names>S</given-names></name><name><surname>Randow</surname><given-names>F</given-names></name><name><surname>Lehner</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Proteomic plasma membrane profiling reveals an essential role for GP96 in the cell surface expression of LDLR family members, including the LDL receptor and lrp6</article-title><source>Journal of Proteome Research</source><volume>11</volume><fpage>1475</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1021/pr201135e</pub-id><pub-id pub-id-type="pmid">22292497</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Jin</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>GPS 2.1: Enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection</article-title><source>Protein Engineering, Design &amp; Selection</source><volume>24</volume><fpage>255</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1093/protein/gzq094</pub-id><pub-id pub-id-type="pmid">21062758</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yusoff</surname><given-names>PAM</given-names></name><name><surname>Woutersen</surname><given-names>DTJ</given-names></name><name><surname>Goh</surname><given-names>P</given-names></name><name><surname>Harmston</surname><given-names>N</given-names></name><name><surname>Smits</surname><given-names>R</given-names></name><name><surname>Epstein</surname><given-names>DM</given-names></name><name><surname>Virshup</surname><given-names>DM</given-names></name><name><surname>Madan</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The functional landscape of patient-derived RNF43 mutations predicts sensitivity to WNT inhibition</article-title><source>Cancer Research</source><volume>80</volume><fpage>5619</fpage><lpage>5632</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-0957</pub-id><pub-id pub-id-type="pmid">33067269</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein</article-title><source>PNAS</source><volume>94</volume><fpage>9273</fpage><lpage>9278</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.17.9273</pub-id><pub-id pub-id-type="pmid">9256472</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70885.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nusse</surname><given-names>Roel</given-names></name><role>Reviewing Editor</role><aff><institution>Stanford University</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Nusse</surname><given-names>Roel</given-names></name><role>Reviewer</role><aff><institution>Stanford University</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The study presents a novel mode of crosstalk between hepatocyte growth factor (HGF)-MET and Wnt signaling. The receptor tyrosine kinase MET phosphorylates an endocytic motif in the cytosolic tail of the E3 ligase ZNRF3, which is implicated in Wnt signaling. As a result, phosphorylated ZNRF3 is stabilized at the membrane and is prevented from down-regulating Wnt receptors, a process involving endocytosis. The work has implications for both HGF-MET and Wnt signaling. In a broader sense, the work forms a good example of interactions between signaling pathways leading to new ways of regulation.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A MET-PTPRK kinase-phosphatase rheostat controls ZNRF3 and Wnt signalling&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, including Roel Nusse as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Michael Eisen as the Senior Editor.</p><p>As you will see, the reviewers are overall interested in the new data and would put value on the work as it will lead to further understanding of the Wnt pathway. The paper does indeed complement your earlier publication on the role of ZNRF3 phosphorylation.</p><p>However, there is one major concern, something that you no doubt are aware of, and that the use of bafilomycin to prevent lysosomal degradation and stabilize proteins. Both reviewers ask for clarification and what would happen in the absence of bafilomycin.</p><p>Reviewer 2 wonders how general the findings are, as the experiments were performed in a single cell line (H1703).</p><p>Both reviewers raise several other issues that are probably easier to address in a revised version, which we hope you will be able to submit.</p><p><italic>Reviewer #1:</italic></p><p>Kim at al., identify the proto-oncogene MET as a tyrosine kinase on ZNRF3, phosphorylating the 4Y motif which is in itself involved in internalization of the ZNRF3 receptor. They show that MET binds to ZNRF3 and induces 4Y phosphorylation, and is stimulated by the MET ligand HGF. This is important for the understanding of the mechanisms of Wnt signaling, an important developmental signaling pathway. The work is of high quality, with extensive experimental tests and appropriate controls.</p><p>Figure 1 B shows is a diagram with different classes of TM kinases, including a light blue block of &quot;transmembrane tyrosine kinases&quot;. But the grey block above also includes some transmembrane tyrosine kinases. What is the logic of subdivision of these kinases?</p><p>On page 5, it is stated that bafilomycin was added to prevent lysosomal degradation and stabilize the protein. But some experiments, in Figure 4 for example, test whether HGF-MET signalling stabilizes ZNRF3 at the cell surface. What happens to those stabilizing data in the absence of bafilomycin?</p><p>Figure 3 C shows binding data between ZNRF3 and MET, before and after HGF addition to cells. There seems to be a differences between the amount of pMET input (bottom panel), total MET and MET brought down by ZNRF3-HA, comparing 15 and 30 minutes. Perhaps the authors can comment on this.</p><p>The figures are nicely done, with the diagrams. But the yellow zone in Figure 1G is not explained.</p><p><italic>Reviewer #2:</italic></p><p>A previous publication of the Niehrs group identified a regulatory role of the phosphatase PTPRK in promoting ZNRF3-mediated turnover of Wnt receptors (Chang et al., <italic>eLife</italic> 2020). The current study presents a follow-up of this work in which the authors search for the kinase responsible for phosphorylation of the 4Y endocytic motif within the ZNRF3 cytosolic tail. They identify and validate the MET receptor as a kinase of the ZNRF3-4Y motif by using ZNRF3-HA-inducible H1703 cells in combination with siRNAs depletion or overexpression of putative kinases.</p><p>In line, overexpressed ZNRF3 was found in complex with endogenous MET. The role of MET is further confirmed by an HGF-induced increase in ZNRF3 phosphorylation, and decreased 4Y phosphorylation and ZRNF3 internalization upon treatment with Crizotinib, a MET inhibitor. Moreover, HGF treatment was shown to increase the levels of ZNRF3 at the cell surface and, at the same time, prevent ZNRF3-mediated surface removal of the Wnt receptors FZD5 and LRP6.</p><p>Overall, this study adds valuable insights in how the Wnt pathway negative feedback regulator ZNRF3 is regulated by phosphorylation and how these events depend on crosstalk between the Wnt and HGF pathways. Limitations of this study include a lack of support for the broad and biological relevance of the proposed mechanism, and the reliance on the use of bafilomycin treatment in all experiments, which may confound protein trafficking behavior. In addition, the relative contribution of crosstalk between Wnt and HGF pathways at the level of ZNRF3 regulation remains unclear.</p><p>1. All experiments revealing a functional link between MET and ZNRF3 were performed in a single cell line (H1703 cells), and findings in this cell line could not be reproduced in HEK293T cells (discussion). Also, a lack of functional/biological readouts prevents an interpretation of the biological relevance of the presented model. A demonstration that the presented mechanism is conserved and broadly relevant to other cells and model systems would strengthen this study.</p><p>2. The authors state that all experiments were performed in the presence of Bafilomycin A1 (p5), which has many caveats, in particular when evaluating protein trafficking behavior. Can the authors exclude that their findings are a merely a curiosity of conditions in which endosomal acidification is prevented? Based on the literature, endosomal organization, endocytosis as well as recycling rates are affected by these conditions. To substantiate the proposed model, at least some of the functional experiments (e.g. HGF treatment-mediated alterations in β-catenin levels, ZNRF3 cell surface stabilization, FZD and LRP6 turnover assays) should be performed in absence of the drug.</p><p>3. For HGF and Wnt pathways, multiple points of crosstalk have been reported. To judge the relative contribution of HGF-MET regulation of ZNRF3 versus previously reported crosstalk events, the levels of HGF-induced β-catenin stabilization and β-catenin-dependent reporter activity should be evaluated in ZNRF3/RNF43-ko cells.</p><p>4. The authors make a comparison between the activities HGF and RSPO. Both factors mediate pathway activation by acting on ZRNF3, albeit by different mechanisms that involve either ZNRF3 stabilization at the plasma membrane (HGF) or an increase in ZNRF3 turnover (RSPO). The outcome of both pathways is Wnt receptor stabilization. To judge the relative contribution of HGF-mediated pathway stimulation, can the authors make a direct comparison of RSPO and HGF-mediated potentiation of Wnt-induced pathway activation, using reporter assays? Also, do these pathways act synergistically?</p><p>5. In line 234-236, the authors speculate that HGF inhibition might be beneficial for treatment of WNT-dependent cancers. However, as WNT-dependent colorectal cancers commonly display a lack of ZNRF3 expression, either due to mutation or gene silencing (e.g. Lannagan et al., Gut 2019), this poses a conceptual problem.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70885.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>Kim at al., identify the proto-oncogene MET as a tyrosine kinase on ZNRF3, phosphorylating the 4Y motif which is in itself involved in internalization of the ZNRF3 receptor. They show that MET binds to ZNRF3 and induces 4Y phosphorylation, and is stimulated by the MET ligand HGF. This is important for the understanding of the mechanisms of Wnt signaling, an important developmental signaling pathway. The work is of high quality, with extensive experimental tests and appropriate controls.</p><p>Figure 1 B shows is a diagram with different classes of TM kinases, including a light blue block of &quot;transmembrane tyrosine kinases&quot;. But the grey block above also includes some transmembrane tyrosine kinases. What is the logic of subdivision of these kinases?</p></disp-quote><p>The grey block represents PTKs from in silico tyrosine kinase prediction. In addition, we have manually added several transmembrane or cortical localized TKs from literature search (blue and light blue blocks). We realized that this misunderstanding is due to inaccurate labeling for the diagram and have clarified this point.</p><disp-quote content-type="editor-comment"><p>On page 5, it is stated that bafilomycin was added to prevent lysosomal degradation and stabilize the protein. But some experiments, in Figure 4 for example, test whether HGF-MET signalling stabilizes ZNRF3 at the cell surface. What happens to those stabilizing data in the absence of bafilomycin?</p></disp-quote><p>We apologize for the misunderstanding regarding bafilomycin treatment (p5). Bafilomycin was only used in the few western blot analyses that analyzed pTyr-ZNRF3, because the tyrosine phosphorylation signal is very weak and labile. Bafilomycin was not added in any other experiments. The bafilomycin trick to boost pTyr-ZNRF3 was already employed in Chang et al., where we demonstrated qualitatively the same- but weaker effects without bafilomycin (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>) . We now have modified the sentence.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Bafilomycin treatment enhances pTyr-ZNRF3 levels.</title><p>Tyrosine phosphorylation of ZNRF3 in TetOn ZNRF3-HA H1703 cells upon siRNA transfection with or without bafilomycin treatment overnight. Cells were treated with Dox for 48 hr before harvest. As a positive control, cells were treated with Na-pervanadate (PV, phosphatase inhibitor) for 30 min before harvest. Lysates were pulled down with anti-HA antibody or control IgG and subjected to Western blot analysis. Ratio, tyrosine phosphorylation of ZNRF3 normalized to total ZNRF3. Note that bafilomycin is enhancing pTyr-ZNRF3 levels but does not qualitatively affect the siPTPRK outcome.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70885-sa2-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>Figure 3 C shows binding data between ZNRF3 and MET, before and after HGF addition to cells. There seems to be a differences between the amount of pMET input (bottom panel), total MET and MET brought down by ZNRF3-HA, comparing 15 and 30 minutes. Perhaps the authors can comment on this.</p></disp-quote><p>Upon HGF stimulation, MET is recognized by the E3 ligase CBL and is subjected to ubiquitin mediated proteasomal degradation (PMID: 12244174). This negative feedback likely causes decreasing MET levels. The fact that HGF induces binding of ZNRF3 to MET despite decreasing MET levels, emphasizes the significance of the HGF effect.</p><disp-quote content-type="editor-comment"><p>The figures are nicely done, with the diagrams. But the yellow zone in Figure 1G is not explained.</p></disp-quote><p>We have now removed the yellow zone.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>1. All experiments revealing a functional link between MET and ZNRF3 were performed in a single cell line (H1703 cells), and findings in this cell line could not be reproduced in HEK293T cells (discussion). Also, a lack of functional/biological readouts prevents an interpretation of the biological relevance of the presented model. A demonstration that the presented mechanism is conserved and broadly relevant to other cells and model systems would strengthen this study.</p></disp-quote><p>We now tested also an alternative lung adenocarcinoma cell line, H3122, and inhibiting MET with Crizotinib reduced mature LRP6, an effect that was abolished when ZNRF3/RNF43 where siRNA-inhibited (Figure 5 —figure supplement 1A). This result supports that MET regulates WNT receptors via ZNRF3/RNF43 also in H3122 cells.</p><disp-quote content-type="editor-comment"><p>2. The authors state that all experiments were performed in the presence of Bafilomycin A1 (p5), which has many caveats, in particular when evaluating protein trafficking behavior. Can the authors exclude that their findings are a merely a curiosity of conditions in which endosomal acidification is prevented? Based on the literature, endosomal organization, endocytosis as well as recycling rates are affected by these conditions. To substantiate the proposed model, at least some of the functional experiments (e.g. HGF treatment-mediated alterations in β-catenin levels, ZNRF3 cell surface stabilization, FZD and LRP6 turnover assays) should be performed in absence of the drug.</p></disp-quote><p>We apologize for the misunderstanding regarding bafilomycin treatment (p5). Bafilomycin was only used in the few western blot analyses which analyzed pTyr-ZNRF3, because the tyrosine phosphorylation signal is very weak and labile. Bafilomycin was <italic>not</italic> added in any other experiments. The bafilomycin trick to boost pTyr-ZNRF3 was already employed in Chang et al., where we demonstrated qualitatively the same- but weaker effects without bafilomycin (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>) . We now have modified the sentence.</p><disp-quote content-type="editor-comment"><p>3. For HGF and Wnt pathways, multiple points of crosstalk have been reported. To judge the relative contribution of HGF-MET regulation of ZNRF3 versus previously reported crosstalk events, the levels of HGF-induced β-catenin stabilization and β-catenin-dependent reporter activity should be evaluated in ZNRF3/RNF43-ko cells.</p></disp-quote><p>Previously described HGF effects on Wnt signalling act downstream of ligand-receptor signalling. However, in H1703 cells such downstream-acting mechanisms that bypass Wnts seem not to be involved since without Wnt3a HGF did not induce b-catenin accumulation (Figure 5D-E). Moreover, we carried out the experiment you suggested, albeit with siRNA instead of ZNRF3/RNF43-ko cells, to safe time: Wnt3a-induced β-catenin was enhanced two-fold by HGF treatment and siZNRF3/RNF43 blocked this effect (Figure 5 —figure supplement 1C). This result confirms that at least in in H1703 cells, HGF cross-talk with Wnt signalling is mostly by the here-described mechanism.</p><disp-quote content-type="editor-comment"><p>4. The authors make a comparison between the activities HGF and RSPO. Both factors mediate pathway activation by acting on ZRNF3, albeit by different mechanisms that involve either ZNRF3 stabilization at the plasma membrane (HGF) or an increase in ZNRF3 turnover (RSPO). The outcome of both pathways is Wnt receptor stabilization. To judge the relative contribution of HGF-mediated pathway stimulation, can the authors make a direct comparison of RSPO and HGF-mediated potentiation of Wnt-induced pathway activation, using reporter assays? Also, do these pathways act synergistically?</p></disp-quote><p>We now compared side-by-side HGF and RSPO in Wnt stimulation (<xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>) . Both RSPO1 and HGF enhanced Wnt3a induced β-catenin dose dependently and to about the same extend. However, the profiles were different. While RSPO1 induced a monotonic increase, the HGF effect decreased at higher doses, possibly because of too high MET internalization.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>Comparison of recombinant human RSPO1 and HGF in Wnt activation.</title><p>Immunoblot analysis of cytosolic β-catenin in H1703 cells upon 2h treatment of Wnt3a with different concentrations of recombinant human HGF or RSPO1. Ratio, relative levels of β-catenin normalized to GAPDH. Data show a representative result from two independent experiments with similar outcome.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70885-sa2-fig2-v2.tif"/></fig><p>We now also tested for HGF and RSPO synergism. We treated cells with a sub-optimal dose of Wnt3a and added HGF or RSPO3 alone or in combination and then monitored b-catenin accumulation. Interestingly, HGF and RSPO3 strongly synergized in inducing b-catenin accumulation (Figure 5 —figure supplement 1D). This observation suggests that HGF and RSPO act non-redundantly to target distinct ZNRF3 pools. This impressive synergism also suggests that HGF may be useful in growing Wnt-dependent organoids. Thank you for suggesting this experiment, which led to an interesting finding!</p><disp-quote content-type="editor-comment"><p>5. In line 234-236, the authors speculate that HGF inhibition might be beneficial for treatment of WNT-dependent cancers. However, as WNT-dependent colorectal cancers commonly display a lack of ZNRF3 expression, either due to mutation or gene silencing (e.g. Lannagan et al., Gut 2019), this poses a conceptual problem.</p></disp-quote><p>Not all CRCs lack ZNRF3 expression. For example, Bond et al. (PMID: 27661107) found no significant change on ZNRF3 expression between BRAF<sup>V600E</sup> and matched normal mucosa samples. Moreover, 8% of CRCs show high expression of RSPO2/3, which is mutually exclusive with RNF43 mutation (Kleeman and Leedham 2020, PMID: 33202731), suggesting that in those CRCs hyperactivation of WNT pathway is achieved via RSPO driven ZNRF3/RNF43 sequestration. Finally, Storm et al. (Storm et al., 2016, PMID: 26700806) showed that PTPRK-RSPO3-fusion triggers CRC, and in all likelihood via ZNRF3/RNF43. Some of these CRCs may benefit from MET inhibition.</p></body></sub-article></article>